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Following emerging evidence that neurodegenerative processes in multiple sclerosis (MS) are present from its early stages, an
intensive scientiﬁcinterest has been directed to biomarkersof neuro-axonaldamagein body ﬂuids ofMS patients.Recent research
has introduced new candidate biomarkers but also elucidated pathogenetic and clinical relevance of the well-known ones. This
paper reviews the existing data on blood and cerebrospinal ﬂuid biomarkers of neuroaxonal damage in MS and highlights their
relation to clinical parameters, as well as their potential predictive value to estimate future disease course, disability, and treatment
response. Strategies for future research in this ﬁeld are suggested.
1.Introduction
Multiple sclerosis (MS) is a chronic disease of the cen-
tral nervous system (CNS) characterized by unpredictable
clinical relapses and remissions and/or by progression of
disability over time [1]. Relapses are considered to be
the clinical expression of acute inﬂammation in the CNS,
whereas progression reﬂects chronic demyelination, gliosis,
and axonal loss [2]. Although axonal/neuronal damage has
been recognized in MS for more than a century [3], a
refocused interest on the role of axonal pathology and
neurodegeneration as the cause of permanent neurological
disability in MS patients appeared since the 1990s [4–
9]. The development of new immunostaining protocols
and new magnetic resonance imaging (MRI) techniques
has enabled earlier detection of more subtle changes in
diﬀuse neuroaxonal pathology not only within focal white
matter [6, 10] and gray matter lesions [11–13], but also
within normal appearing white matter (NAWM) [14–16]
and normal appearing gray matter in MS [14, 15]. Current
evidence suggests that axonal loss occurs at an early stage of
MS[6,17],butbecauseofCNScompensatorymechanisms it
remains clinically silent until a threshold level of axonal loss
is achieved and the functional reserve capacity is exhausted
[9, 18]. Subsequent progressive axonal loss underlies a con-
tinuous and irreversible neurological decline [19], causing
a transition from initially relapsing remitting (RR) to the
secondary-progressive (SP) MS [7, 9].
Since inﬂammation correlates only poorly with dis-
ability and the loss of neurons and axons may be sub-
ject to biochemical monitoring [20], biochemical markers
of neuroaxonal degeneration gain increasing importance.
Such biomarkers could provide tools for development and
evaluation of new therapeutic strategies [21]a n dm i g h t
serve as prescreening tools and/or cross-sectional surrogate
endpoints in MS clinical trials [22, 23], more importantly
in those testing potentially axon-protective compounds [24].
Additionally, the assessment of neuroaxonal biomarkers
could help in better understanding of MS pathogenesis and
identiﬁcation of disease subtypes [22], as well as in routine
patient management for (1) prediction of conversion to
MS after a ﬁrst clinical episode, (2) early prediction of
disease course and future disability, (3) selection of patients
for individually tailored treatments, and (4) monitoring of
disease activity and individual treatment response [23, 25–
27]. However, it is unlikely that a single biomarker could
serve for any of these aims due to the extreme complexity
o ft h ep a t h o g e n e t i cp r o c e s s e sw h i c hc a u s et i s s u ed a m a g ea n d
neuroaxonal loss in MS [26].
Recent research has introduced new candidate biomark-
ers but also elucidated pathogenetic and clinical relevance2 Multiple Sclerosis International
of the well-known ones. This paper reviews the existing
data on blood and cerebrospinal ﬂuid (CSF) biomarkers
of neuroaxonal damage in MS in the light of their clinical
relevance and suggests strategies for future research in this
ﬁeld.
2.Mechanisms of Neuroaxonal Damagein MS
The mechanisms leading to axonal damage in MS are essen-
tially not well elucidated [21]. However, challenging some
clinical [28–30], neuroradiological [31], and neuropatho-
logical [11, 32] observations that neurodegeneration in MS
might progress independently from or even precede the
inﬂammation, recent neuropathological reports conﬁrmed
the positive correlation between axonal pathology and the
degree of inﬂammation even in cases with progressive MS
[33,34].Thisfurthersupportsthescenarioinwhich avariety
of eﬀectors from the inﬂammatory microenvironment could
injure axons, such as direct attack by autoreactive antibodies
[35–37]o rc y t o t o x i cC D 8 +T-cells [36, 38, 39], invading
macrophages, proteolytic enzymes, cytokines, nitric oxide
[39–41]a n df r e er a d i c a l s[ 42, 43], defects in calcium home-
ostasis [21], glutamate-mediated excitotoxicity [43, 44], an
increased axonal energy demand [45], and mitochondrial
injury and failure [45, 46]( F i g u r e1). Axonal damage could
also be secondary to acute or chronic demyelination [6, 47],
damaging changes in sodium channel distribution [2, 48],
and disruption of axonal/glial interactions [49, 50]a sw e l l
as related to the lack of myelin-derived trophic depriva-
tion and/or impaired axonal regeneration by axon growth
inhibitory molecules including those from myelin debris
recently called myelin-associated inhibitory factors (MAIFs)
such as myelin-associated glycoprotein, oligodendrocyte
myelin glycoprotein, Nogo-A, semaphorin 4D/CD100, and
ephrin B3 [51, 52]( F i g u r e1).
3.Biomarkersof Neuroaxonal Damage in
MultipleSclerosis
Following damaging processes, molecules released from
neuronal cytoplasm, membrane, or nucleus are released into
the extracellular CNS compartment (Figure 2)a n dt h e i r
further metabolic, transport, and reuptake mechanisms,
drainage pathways or other interactions with the CNS tissue,
as well as the degree of tissue destruction would determine
the level of these substances in CSF and blood [21].
CSF analysis is more pathology speciﬁc as it provides
information from the body ﬂuid that is most closely asso-
ciated to the disease process [53], but sometimes substances
measured in lumbar-sac-CSF are not necessarily completely
representative of brain pathology [20]. However, there is a
needfornewbiomarkersinmoreeasilyaccessiblebodyﬂuids
such as peripheral blood [53], since substances produced
within the CNS and found in the blood could also be
representative of the ongoing CNS pathology [20].
CSF and/or blood levels of biomarkers associated with
neuroaxonal injury in patients with MS and clinically
isolated syndrome suggestive of MS(CIS)are summarized in
MAIFs
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Figure 1: The mechanisms of neuroaxonal damage in multiple
sclerosis. Legend: NO: nitric oxide; M: macrophage; C: comple-
ment; Ab: antibody; CD8+T: CD8+T-lymphocyte; MAIFs: myelin-
associated inhibitory factors.
Tables 1, 3, 4 and 5 and their relation to clinical parameters
in Table 2.
3.1. Neuroﬁlaments. Neuroﬁlaments (NFs) are cytoskeletal
proteins which play a role in stabilizing axons, determining
axon diameter and participate in axonal transport [54, 55].
As NFs are found exclusively within neurons, their detection
in blood or CSF therefore reﬂects neuronal and axonal
damage [56]. Mammalian NFs consist of diﬀerent subunits:
NF-light chain (NF-L), which serves as a backbone for NF-
intermediate chain (NF-M) and a heavy chain (NF-H) to
copolymerise [21]. The most abundant, the smallest and
most soluble NF subunit is NF-L but is susceptible to
proteases [57]. On the other hand, HF-His a larger molecule
and more resistant to proteases if phosphorylated [58].
Phosphorylated parts of NF molecules are mostly abundant
within HF-M and NF-H subunits [59], and the state of
phosphorylation inﬂuencesaxonal diameter[60].The highly
phosphorylated NF-H are normally found only in axonal
NFs and this marker is thought to indicate axonal injury
and/or degeneration [56], whereas NF-L constitutes only a
minor part of the neuronal cell body and dendrites relative
to axons [61]. NF-H phosphorylation may increase during
theprogressive phase ofMS [62].Duetothe lowermolecular
weight of NF-L and/or its lower phosphorylation rate, NF-L
could diﬀuse earlier from the parenchyma into CSF than
NF-H, but also could be degraded quicker [54]. Although
changesintheblood-brainbarrier(BBB)mightinﬂuencethe
CSF NF-L concentration, the degree of such inﬂuence was
considered to be negligible [61].Multiple Sclerosis International 3
Table 1:Neuroﬁlamentsubunitsinthecerebrospinal ﬂuid(CSF)andbloodofpatientswithmultiplesclerosis(MS)and/orclinicallyisolated
syndrome suggestive of MS (CIS).
Biomarker
(subtype) Body ﬂuid Immunoassay Number of patients Main ﬁndings REF
NF-L (cytoplasmic)
CSF ELISA 60 MS (RR) RR ↑↑ HCo [61]
CSF Dot-blot 35 MS (RR/SP/PP) MS ↑↑ OIND or NIND, PP/SP ↑↑ RR [63]
CSF ELISA 66 MS (RR/SP) RR/SP ↑↑ HCo [64]
CSF ELISA 99 MS (RR/SP/PP/PR) RR/SP/PP ↑↑ NHCo, SP the highest [65]
CSF ELISA 51 MS (RR/SP/PP) not detected [66]
CSF ELISA 47 MS MS ↑↑ healthy siblings or HCo [67]
CSF ELISA 76 MS (RR/SP/PP) + 38 CIS CIS+MS ↑↑ NIND+OIND + NHCo [54]
CSF ELISA 5 MS (RR) MS ↑↑ NHCo [68]
NF-M (cytoplasmic) CSF/PL/SE not
investigated —— —
NF-H (cytoplasmic)
CSF ELISA 38 MS (RR) + 52 CIS NF-HSMI35 in CIS ↑↑ NHCo [25]
CSF ELISA 41 ON NF-HSMI34 and NF-HSMI34/SMI35 in ON ↑↑
OND [69]
CSF ELISA 51 MS (RR/SP/PP) NF-HSMI35 RR ↔ SP ↔ PP [66]
CSF ELISA 34 MS (RR/SP/PP) NF-HSMI34 in PP/SP ↑↑ RR, NF-HSMI35 in
SP/PP ↑↑ RR [62]
CSF ECL 95 MS MS ↑↑ NHCo [23]
CSF ELISA 24 MS (RR/SP/PP) NF-HSMI35 in SP ↑ RR [70]
PL ELISA 18 ON NF-HSMI35 in ON ↑↑ HCo [71]
CSF ELISA 34 MS (RR) NF-HSMI35 in MS ↑↑ NHCo [72]
CSF ELISA 76 MS (RR/SP/PP) + 38 CIS NF-HSMI35 in MS+CIS ↑↑ NHCo + NIND
+O I N D [54]
REF: reference; NF-L: neuroﬁlament-light chain; NF-M: neuroﬁlament-intermediate chain; NF-H: neuroﬁlament-heavy chain; PL: plasma; SE: serum;
ELISA: Enzyme-Linked Immunosorbent Assay; ECL: Electrochemiluminescence-basedsolid-phase sandwich immunoassay; RR: relapsing-remitting MS;S P :
secondary-progressiveMS;PP:primary-progressiveMS;ON: opticneuritis;NF-HSMI35:NF -Hph o sph o rylat edfo r m;NF -H SMI34:NF - Hh yperph o sph o rylat ed
form; ↑↑ signiﬁcantly higher than; ↑ higher than; ↔ no diﬀerence between; HCo: healthy controls; OIND: other inﬂammatory neurological diseases; NIND:
noninﬂammatory neurological disorders; NHCo: neurologically healthy controls; OND: other neurological diseases.
Healthy individuals have no NF-L in their CSF, whereas
most people with neurological disorders, such as amy-
otrophiclateral sclerosis, stroke,MS and Alzheimer’s disease,
can have elevated levels [73]. Several studies have shown
the increase of the CSF NF-L levels in MS or CIS patients
(Table 1) ,i nt h el a t t e rm o r es oi nt h o s ew h oc o n v e r t e dt o
MS within 3 years [54]. On the other hand, CSF NF-L was
detectable at low concentrations [74], or even undetectable
in some other studies albeit the assay was similar to that
used by others [66]. CSF NF-L levels were reported to be
increased during acute relapses [54, 64], in patients with
enhancingMRIlesions[54],aswell asinpatientswithhigher
relapse rate [61]( T a b l e2) and were also shown to have
a peak during the ﬁrst two months after the start of the
previousexacerbation and to gradually decrease thereafter to
al o wl e v e l[ 61]. A correlation between NF-L with Expanded
Disability Status Scale (EDSS) score as a disability measure
was found in some studies [54, 63]. Norgren et al. [65]
reported a signiﬁcant correlation between CSF NF-L levels
and progression index over 10 years whereas in a recent
study the risk for high Multiple Sclerosis Severity Score
(MSSS) at long-term follow-up after 14 years was increased
threefold for cases with high NF-L levels [75]. Conversion
from RRMS to SPMS was more likely in cases with high CSF
NF-L levels when compared with those with undetectable or
intermediate NF-L levels [75]( T a b l e2). Other authors could
not demonstrate any correlation with disability measures
[64, 66]. In some studies CSF NF-L concentration did not
correlate with gender or age [61, 64, 66, 67]o rd i s e a s e
duration [64, 65], but in some reports CSF NF-L levels were
found to increase with age [68]. Blood NF-L levels have not
been reported to date (Table 1).
NF-Msubunithas notbeen analysed so far in body ﬂuids
of MS patients.
In patients with optic neuritis (ON), the levels of NF-
H phosphorylated form (NF-HSMI35)i np l a s m a[ 71], or its
hyperphosphorylated form in CSF (NF-HSMI34)[ 69], as well
as CSF NF-HSMI35 levels in CIS patients [25], were found
to be signiﬁcantly higher compared to controls (Table 1).
Signiﬁcantly higher CSF NF-H levels in MS patients than in
control subjects (Table 1) were also reported in severalrecent
studies (Table 1)[ 23, 54, 72], with higher [70], or signiﬁ-
cantly higher [54, 62] levels in patients with a progressive
course.Oppositetotheseﬁndings, nodiﬀerenceinCSFlevels
of this biomarker was found between RR, SP and primary
progressive (PP) MS patients by Eikelenboom et al. [66].
In some studies, CSF NF-H levels correlated signiﬁcantly
with EDSS score both in CIS [25] and MS patients [54, 62].4 Multiple Sclerosis International
Table 2: Biomarkers of neuroaxonal damage in patients with multiple sclerosis (MS) and/or clinically isolated syndrome suggestive of MS
(CIS) in relation to clinical parameters.
Biomarker
Correlation
with
disability∗
Correlation
with disease
activity∗
Prediction of
CIS
conversion to
CDMS∗
Prediction of
future disease
course∗
Prediction of
future
disability∗
Prediction of
treatment
response∗
NF-L 4 (308) +
2 (117) − 4 (339) + 1 (38) + 1 (95) + 3 (308) + —
Anti-NF-L 3 (180) +
2 (181) − —————
Anti-NF-M 1 (47) +
1 (49) − —————
NF-H 5 (256) +
2 (81) −
3 (254) +
1 (30) − 1 (52) + 1 (34) + 3 (86) + 1 (30)∗∗ +
1 (32) +
Anti-NF-H 1 (67) +
1 (51) − —————
Tubulin 1 (35) + — — — — —
Antitubulin 1 (67) +
2 (81) − —————
Actin 1 (35) + — — — — —
Tau 1 (90) +
4 (218 ) −
3 (179) +
1 (90) −
1 (52)∗∗ +
1 (53) − 1 (32) + 1 (32) +
1 (53) − —
Amyloid β42 1 (21) − 1(21) + — — — —
BACE1 — — — — 1 (100) − —
NAA 2 (160) + — — — — —
A p o - E ——————
NSE 1 (64) +
2 (87) − —————
GAP-43 1 (49)∗∗ + —————
24S-OH-chol 1 (118) + 2 (206) + — — — —
14-3-3 2 (82) + 1 (38) + 2 (123) + — 2 (101) + —
∗Number of positive (+) or negative (−) studies with total number of patients included (in brackets); ∗∗a tendency; CDMS: clinically deﬁnite MS; NF-L:
neuroﬁlament-light chain; Anti-NF-L: antibodies to NF-L; Anti-NF-M: antibodies to neuroﬁlament-intermediate chain; NF-H: neuroﬁlament-heavy chain;
Anti-NF-H: antibodies to NF-H; BACE1: β-site amyloid precursor protein-cleaving enzyme 1; NAA: N-acetylaspartate; Apo-E: apolipoprotein-E; NSE:
neuron-speciﬁc enolase; GAP-43: growth-associated protein 43; 24S-OH-chol: 24S-hydroxycholesterol.
CSF NF-H levels also signiﬁcantly correlated with the
ambulation index and the nine-hole-peg test scores [62], as
well as with the MSSS [76]. In the latter study the degree
of NF phosphorylation (ratio, hyperphosphorylated versus
phosphorylated NF-H) was 8-fold higher in severely versus
mildly disabled patients [76], whereas no correlation of
NF-H levels with EDSS was found in some other studies in
CSF [66]o rp l a s m a[ 77]. The highest CSF NF-H levels were
found during relapses [25, 54] or correlated with MRI lesion
enhancement [78], but Petzold et al. found no correlation of
plasma HF-HSMI35 with the relapse rate [77]. In the study of
Brettschneideret al., the sensitivity for predicting conversion
to clinically deﬁnite (CD) MS after CIS was generally low,
but could be increased by combining MRI with CSF NF-H
criteria [25]. Additionally, a tendency towards a higher
RRMS to SPMS conversion rate over 3 years in patients
with high CSF NF-H levels was also shown [62]. Moreover,
Petzold et al. [71] found signiﬁcantly higher plasma NF-H
levelsin ONpatientswith poorrecovery ofvisual acuitythan
in those with good recovery. In the study of Lim et al., in
which 8/18 patients in the ON trial and 15/32 subjects in the
MS attack trial were treated with oral methylprednisolone,
in the MS attack trial group, CSF NF-HSMI34 and NF-HSMI35
measured at week 3 and CSF NF-HSMI34 levels from baseline
toweek3werepredictiveofclinicaloutcomeatweek8and52
[78]. In the study of Rejdak et al., CSF NF-H levels inversely
correlated with the EDSS recovery grade over a short-term
follow-up of6–8weeks[72].Moreover, in30RRMSpatients,
plasma NF-HSMI35 levels were higher, albeit nonsigniﬁcantly,
in nonresponders than in responders to IFN beta1-a or 1-
b over 1 year of treatment [77]. A correlation of CSF NF-
H levels with age was found in CIS or MS patients in some
studies [54], but in the others no age inﬂuence [62, 66]o ra
correlation with disease duration was found [66, 72].
3.2. Antineuroﬁlament Antibodies. Axonal damage and sub-
sequentexposureofNFscouldleadtoantibodygenerationin
a T-cell-dependent secondary immune response to a foreign
antigen [85]. Cytoskeletal and myelin debris, released byMultiple Sclerosis International 5
Table 3: Parameters of humoral and cellular response to markers of neuroaxonal damage in the cerebrospinal ﬂuid (CSF) and blood of
patients with multiple sclerosis (MS) and clinically isolated syndrome suggestive of MS (CIS).
Biomarker Body ﬂuid Immunoassay Number of patients Main ﬁndings REF
Anti-NF-L
CSF/SE ELISA (IgG) 67 MS (RR/SP/PP)
CSF/SE index in PP or SP
↑↑ RR or
OIND/NIND/NHCo
[74]
CSF/SE ELISA (IgM, IgG) 58 MS (RR/SP/PP)
+8C I S
speciﬁc IgG-index in MS ↑↑
CD [79]
CSF/SE ELISA (IgG) 51 MS (RR/SP/PP)
CSF/SE index correlated
with brain atrophy, RR ↔
SP ↔ PP
[66]
CSF/SE ELISA (IgG) 130 MS
(RR/SP/PP)
serum antibody levels in PP
↑↑ OND or HCo [80]
Anti-NF-M
CSF/SE ELISA (IgG) 47 MS (RR/SP/PP)
signiﬁcant correlation with
anti-NF-L and antitubulin
IgG in serum and CSF
[81]
CSF/SE ELISA (IgG, IgM) 49 MS (RR/SP/PP)
IgM and IgG speciﬁc
indices in MS subgroups ↑↑
CD or CN
[82]
Anti-NF-H CSF/SE ELISA (IgG) 51 MS (RR/SP/PP) RR ↔ SP ↔ PP [66]
CSF/SE ELISA (IgG) 67 MS (RR/SP/PP) MS ↔ OIND/NIND/NHCo [74]
Antitubulin
CSF/SE ELISA (IgG) 67 MS (RR/SP/PP) MS ↔ OIND/NIND/NHCo [74]
CSF/SE ELISA (IgG) 47 MS (RR/SP/PP)
signiﬁcant correlation with
anti-NF-L and anti-NF-M
IgG in serum and CSF
[81]
CSF/SE ELISA (IgG) 29 MS (RR/SP/PP)
+5 C I S
CSF levels in MS+CIS ↑↑
CN [83]
Anti-NSE
T-cell
response
PBMC
T-cell
Proliferation
Assay
35 MS prevalence of response in
MS ↑↑ HCo [84]
REF: reference; Anti-NF-L: antibodies to neuroﬁlament-light chain; anti-NF-M: antibodies to neuroﬁlament-intermediate chain; anti-NF-H: antibodies to
neuroﬁlament-heavy chain; NSE: neuron-speciﬁc enolase; SE: serum; PBMC: peripheral blood mononuclear cells; ELISA: Enzyme-Linked Immunosorbent
Assay; IgG: immunoglobulin G, IgM: immunoglobulin M; RR: relapsing-remitting MS; SP: secondary-progressive MS; PP: primary-progressive MS; ↑↑
signiﬁcantlyhigherthan; ↔no diﬀerencebetween;OIND: otherinﬂammatoryneurologicaldiseases;NIND: noninﬂammatory neurologicaldisorders;NHCo:
neurologically healthy controls; CD: miscellaneous neurological diseases; OND: other neurological diseases; HCo: healthy controls, CN: normal controls
(vertigo, headache, psychogenic syndrome, and fatigue).
neurons, are removed by macrophages which may be able
to reach the peripheral lymph nodes [86]. Additionally, anti-
NF-antibodiescouldbeinducedfromexposuretoexogenous
agents, possibly virus-derived peptides and subseqently may
cross-react with neuronal antigens [87].
Autoimmune responses to neuronal antigens might con-
tribute to axonal damage and irreversible disability in MS
[12], but could also be an epiphenomenon [79]. In the
latter study, intrathecal immunoglobulin (Ig) G and IgM
anti-NF-L synthesis did not diﬀer between MS subgroups
(RR, SP, or PP) or between CIS, MS patients, or healthy
controls [79]( T a b l e3). On the other hand, the intrathecal
anti-NF-L IgG was shown to correlate with MRI parameters
of cerebral atrophy [66] and NF-L-autoimmunity has been
also recently reported to be pathogenic in mice [12].
Additionally, anti-NF-L-IgG levels in serum were found to
be signiﬁcantly increased in PPMS patients compared to
other neurological diseases or healthy controls [80]a n di n
some studies a speciﬁc CSF/serum anti-NF-L IgG index
correlated with EDSS or MSSS scores [74, 81]( T a b l e2). In
some reports, anti-NF-L levels did not correlate with age or
diseasedurationorEDSSscore[66,80],althoughsomeother
authors showed a correlation between both anti-NF-L IgG
index and CSF anti-NF-L IgG and duration of symptoms
before lumbar puncture [74].
Anti-NF-M antibody response was analyzed in MS in a
few studies. In a study of Bartoˇ se ta l . ,t h ee x t e n to fa n t i -
NF-M antibody levels did not correspond to any individual-
ized clinical proﬁles of MS patients although the intrathecal
production of IgM and IgG anti-NF-M was signiﬁcantly
increased in all MS subgroups compared to patients with
other diseases or healthy controls [82]( T a b l e3). In the latter
study [82], the intrathecal IgG and IgM anti-NF-M synthesis
inMSpatientswasunrelatedtogender,age,diseaseduration,
and EDSS score, but Fialov´ ae ta l .[ 81] found a correlation
between anti-NF-M IgG intrathecal synthesis and disability.
Anti-NF-H IgG in CSF/serum was found to be similar
in MS patients and controls [74] and between RR, SP, and
PPMS patients [66]( T a b l e3). The intrathecal production
of anti-NF-H IgG correlated with some parameters of brain6 Multiple Sclerosis International
atrophysuchastheparenchymal fraction[74].TheCSFanti-
NF-H levels correlated with the duration of disease before
lumbar puncture and EDSS score in the study of Silber et al.
[74],butnocorrelationwithEDSSwasshownbyothers[66].
3.3. Tubulin and Antitubulin Antibodies. In addition to NFs,
the other major component of the axonal cytoskeleton is
the microtubule, which mainly consists of α and β tubulin
subunits [21], but also of microtubule-associated proteins
(MAPs) such as MAP2 and tau [88]. Tubulin comprises as
much as 20% of the cellular protein in brain [89]a n di s
mainly responsible for axonal migration and longitudinal
growth as well as for providing the conduit for fast axonal
transport [90]. CSFtubulinlevelswere found tobe increased
in progressive MS (SP+PP) patients as compared to RRMS
or controls [63]( T a b l e4). Antitubulin antibodies were
also investigated and in some studies CSF levels of these
antibodies were shown to be increased in MS patients [83],
aﬁ n d i n gw h i c hw a sn o ts h o w nb yo t h e r s[ 74]. CSF tubulin
levels [63], but also CSF antibodies to tubulin and the
CSF/serum antitubulin index correlated signiﬁcantly with
EDSSin one study[74], whereas no similar correlations with
disability were found in two other studies [81, 83]( T a b l e2).
No correlations of antitubulin antibodies were found with
age or disease duration [74, 83].
3.4. Actin. A c t i ni st h em a j o rc o m p o n e n to ft h em i c r o ﬁ l a -
ments [21]. CSF actin levels were found to be signiﬁcantly
elevated in MS patients than in the control group, with
higher levels in progressive MS cases and correlated with the
EDSS scores [63]( T a b l e4). Anti-actin antibodies were not
separately investigated in MS patients to date and could also
be detected in normal sera [91].
3.5. Gelsolin. Gelsolin is an actin-binding protein that reg-
ulates actin organization [92] and is expressed in neurons
in addition to the other cells [93]. Additionally, its secreted
isoformcouldbefoundinthecirculation[94]andbelongsto
theextracellularactinscavengersystem[95].Followingsome
preliminary results showing low blood and CSF gelsolin
concentration in 4 MS patients [92], Kulakowska et al.
recently reported signiﬁcantly lower plasma gelsolin levels in
MSsamplesthanin controls,whereas therewasnodiﬀerence
in its CSF levels between the two groups [96]( T a b l e4).
3.6. Tau Protein. Tau is an axonal cytoskeletal protein that is
involved in microtubule assembly and stabilisation [97]a n d
therefore is essential for the eﬃcient axonal transport [98].
Abnormal phosphorylation of tau can lead to the forma-
tion of potentially neurotoxic insoluble tau aggregates that
have been shown to be characteristic features of common
neurodegenerativediseases[97,99,100].Pathologicalstudies
demonstrated the association of abnormally phosphorylated
tau (p-tau) protein with SPMS and PPMS [101, 102]b u t
also the absence of insoluble tau fraction in early MS, thus
indicating the possibility that insoluble tau accumulateswith
disease progression [100, 102].
Total-tau (t-tau) protein and/or p-tau have been inves-
tigated in a respectable number of studies performed in
CIS [25, 54, 103–106] and MS patients (Table 4)a n dt h e
reported results are quite contradictory. Tau protein could
be detectable in serum, but in concentrations that are ten
times lower than in CSF [21]. CSF t-tau levels in CIS have
been reported to be higher than in controls [25], but other
authors found no diﬀerence in t-tau or p-tau compared to
controls [104–106]( T a b l e4). In some MS studies, CSF levels
of t-tau [103, 107–110]a n dp - t a u[ 109] were reported to be
signiﬁcantly higher in MS patients than in controls, whereas
some other authors could not conﬁrm these diﬀerences
[54, 104, 111]. T-tau and p-tau were also investigated in
childhood RRMScases in which their CSFlevelswere similar
to controls [112]. A positive correlation of CSF t-tau levels
was shown with EDSS in RRMS and CIS patients [25]a n d
with the progression index over3 years in early RRMS [113],
but in some other studies no correlation with disability in
C I So rM Sw a sd e m o n s t r a t e df o rt h eC S F[ 103, 104, 110]
or serum and CSF levels [105]( T a b l e2). Two studies have
indicated an increased CSF-tau release in clinically active
disease states [109, 114], in one study there was a signiﬁcant
elevation of CSF t-tau among patients with gadolinium-
enhancing brain MRI lesions [103], but the latter ﬁnding
was not conﬁrmed afterwards [25]. However, the relation of
CSF tau levels with the extent of intrathecal inﬂammation
in MS was also supported by ﬁndings of Bartosik-Psujek
and Archelos who showed a signiﬁcant positive correlation
between CSF t-tau levels and IgG index [108]. As shown
by Brettschneider et al., the sensitivity and speciﬁcity of
CSF tau levels for predicting CIS conversion to CDMS was
generallylow,butcouldbeincreased bycombiningwithMRI
parameters or with NF-HSMI35 levels [25]. Gajofatto et al.
[115] could not show a signiﬁcant predictive value of CSF
t-tau in patients with acute myelitis either for conversion to
MS or for disability after a median followup of 6.2 years, but
in the study of Mart´ ınez-Y´ elamos et al. [113], CSF-t-tau was
the only independent variable to predict time to the next
relapse (Table 2). Interestingly, phosphorylation of tau and
axonal pathology were signiﬁcantly reduced when EAE rats
were treated with prednisolone [116], but similar ﬁndings
in MS were not reported. Although CSF t-tau levels were
found associated with age in the control group in the study
of Bartosik-Psujek and Archelos [108], no correlationof CSF
t-tau/p-tau levels with age or disease duration was found in
the majority of other studies [104, 106, 107, 110, 111, 117].
3.7. Amyloid-Precursor Protein and Related Molecules. Amy-
loid precursor protein (APP) probably works as a cargo
receptor for binding proteins during axonal transport [21],
but could have some other important neural functions
including those in memory processes [118]. APP is trans-
ported by a fast anterograde axonal transport [119]a n d
subtle changes in axonal transport or axonal transection
could lead to APP deposits in the axon that are eas-
ily detectable by immunocytochemistry [120]. Based on
immunopathological ﬁndings, it was suggested that APP
accumulation could be a sensitive marker of MS diseaseMultiple Sclerosis International 7
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Figure 2: Membrane, cytoplasmic, and nuclear markers of neuroaxonal damage in the central nervous system (CNS) and their dynamics
within three compartments (extracellular space, cerebrospinal ﬂuid, and blood).
progression [121], but also a potential marker of acute or
active MS [10]. APP is cleaved by an integral membrane
aspartyl protease (β-site APP-cleaving enzyme 1, BACE1),
which results in the release of N-terminal β-cleaved soluble
APP(β-sAPP). TheC-terminal fragmentis further processed
by γ-secretase to yield the amyloid beta (Aβ42) and the
APP intracellular domain [122]. APP can also undergo α-
secretase-mediated cleavage, which results in the release of
the solubile α-sAPP [123].
In the recent study of Mattsson et al. [122], CSF levels
of α-sAPP, β-sAPP, and Aβ42 were signiﬁcantly lower in
MS patients than in controls and patients with ongoing or
recent MS exacerbation had lower α-sAPP levels than stable
MS patients. CSF BACE1 activity was slightly reduced in
patients with MS compared to controls and patients with
SPMS tended to have lower BACE1 activity than patients
with RRMS [122]. Baseline BACE1 activity did not predict
change in EDSS score after 10 years (Table 2)b u tl o wB A C E 1
activity was associated with prolonged MS disease duration
and disease severity. In contrast to controls, a reduction in
BACE1activityover10yearswasseenonlyinRRMS,whereas
patients with SPMS displayed constantly low BACE1 activity
levels [122]. Additionally, two molecules, Bri2 and Bri2-23
have been shown to interact with APP and regulate Aβ42
cleavage and aggregation in vivo [124, 125]. Recent ﬁndings
revealed that CSF levels of Bri2-23, a peptide cleaved from
Bri2,maybeabiomarkerofcerebellar/cognitiondysfunction
in progressive MS patients in which CSF Bri2-23 levels have
been recently shown to be decreased [125]. In a recent study
of Mori et al. [126], CSF Aβ42 levels were signiﬁcantly
lower in cognitively impaired MS patients and were inversely
correlated with MRI parameters of disease activity. On the
contrary, Valiˇ se ta l .[ 106] found a signiﬁcantly higher CSF
Aβ42 levels in MS patients compared to the control group
(Table 4). No study has followed the eﬀect of treatment
on CSF-APP-derived proteins although some preliminary
results in 16 nondemented, non-MS patients indicated a sig-
niﬁcant decrease in CSF Aβ42 levels following corticosteroid
treatment[127].CSFAβ42levelswerenotshowntocorrelate
with age or disease duration [122, 126].
3.8. N-Acetylaspartate. N-Acetylaspartate (NAA) is the
amino acid synthesized and almost exclusively localized in
neurons [128] and is one of the most abundant molecules in
the CNS [129]. Postmortem studies of spinal cords from MS
patients related lower tissue concentrations of NAA to the
lower axonal volume [8]. Several functions of NAAmolecule
in the CNS have been hypothesized, such as (a) an osmolite
to remove water from neurons, (b) an acetate contributor
in myelin sheath synthesis, (c) a mitochondrial energy
source, (d) a precursor for N-acetylaspartyl glutamate, and
(e) a ligand for certain metabotropic glutamate receptors
[130]. Brain proton MR spectroscopy (MRS) allows in vivo
examination of axonalintegrity by quantifying theresonance
intensity of NAA [131]. Previous proton MRS studies have
foundthereducedNAAlevelsinMSlesions,thesurrounding
NAWM and cortical grey matter [132], and a decline in
global MRS-NAA levels was also demonstrated in benign
MS [133]. A decrease in relative NAA levels by proton
MRS was found in patients with CIS in CNS gray matter
[134] and WM lesions [135]. Other studies have shown that
NAA decrease in lesions and NAWM is related to clinical
disability and progressive brain atrophy [136–138]a n dw a s
indicated to bea feature ofprogression [16].Moreover, some
preliminary MRS ﬁndings have shown a beneﬁcial eﬀect of
glatiramer acetate on increase of relative NAA peaks in MS
lesions and NAWM over 2 years [131], whereas relative NAA
peaks had become signiﬁcantly higher in the interferon beta-
lb -treated MS patients following 1 year of treatment [139].
In the study of Jasperse et al. [141], CSF concentrations
of NAAcorrelated with EDSSand MSFunctional Composite8 Multiple Sclerosis International
Table 4: Cytoplasmic, non-neuroﬁlament biomarkers of neuroaxonal damage in the cerebrospinal ﬂuid (CSF) and blood of patients with
multiple sclerosis (MS) and/or clinically isolated syndrome suggestive of MS (CIS).
Biomarker Body ﬂuid Immunoassay Number of patients Main ﬁndings REF
Tubulin CSF Dot-blot 35 MS (RR/SP/PP) MS ↑↑ OIND or NIND, PP/SP ↑↑
RR [63]
Actin CSF Dot-blot 35 MS (RR/SP/PP) MS ↑↑ OIND or NIND, PP/SP ↑↑
RR [63]
Gelsolin CSF/PL Western blot 56 MS PL levels in MS ↓↓ Co∗,C S F
levels in MS ↔ Co∗ [96]
Tau
C S F E L I S A( t - t ) 3 8M S( R R )+5 2C I S C I S↑↑ NHCo [25]
CSF ELISA (t-t) 45 MS (RR/SP/PP) MS ↑↑ OIND + NIND, SP ↔ RR
↔ PP [110]
CSF ELISA (t-t, p-t) 42 RRMS + 18 CIS t-tau and p-tau in MS+CIS↑↑
NHCo, t-tau in CIS ↑↑ NHCo [109]
CSF ELISA (t-t) 38 MS (RR/SP/PP) +
12 CIS MS+CIS↔ NHCo [104]
CSF ELISA (t-t) 76 MS (RR/SP/PP) +
38 CIS MS/CIS ↔ NHCo [54]
CSF ELISA (t-t) 114 MS (RR/SP/PP) MS ↑↑ NIND [108]
CSF ELISA (t-t) 52 MS (RR/SP/PP) +
50 CIS
MS+CIS ↑↑ NHCo, the highest
in CIS [103]
CSF ELISA (t-t) 20 MS
(RR/progressive MS) MS ↔ NHCo [111]
CSF ELISA (t-t) 36 MS (RR/SP/PP) MS ↑↑ NHCo [107]
CSF ELISA (t-t, p-t) 25 RRMS MS ↔ OIND or NIND [112]
CSF/SE ELISA (t-t, p-t) 21 CIS CIS ↔ Co∗∗ [105]
CSF ELISA (t-t, p-t) 14 MS + 9 CIS MS ↔ CIS ↔ NHCo [106]
CSF ELISA (t-t)
43 MS
(RR/SP/PP/PR) + 20
CIS
MS ↔ CIS ↔ NHCo+OND [140]
Amyloid β42 CSF/SE ELISA 21 CIS CIS ↔ Co∗∗ [105]
Amyloid β42 CSF ELISA 14 MS + 9 CIS MS ↑↑NHCo [106]
Amyloid β42 CSF xMAP 100 MS (RR/SP/PP) MS ↓↓ NHCo [122]
α-sAPP CSF Multiplex Assay 100 MS (RR/SP/PP) MS ↓↓ NHCo [122]
β-sAPP CSF Multiplex Assay 100 MS (RR/SP/PP) MS ↓↓ NHCo [122]
Bri2-23 CSF SELDI-TOF 40 MS (SP/PP) MS ↓ OND [125]
NAA CSF GC-MS 76 MS (RR/SP/PP) +
38 CIS
SP ↓↓ RR/CIS, CIS ↔ RR ↔
NHCo [54]
CSF GC-MS 46 MS (RR/SP/PP) MS ↔ OND, SP ↓↓ RR [141]
NSE
CSF Luminescence 66 MS (RR/SP) MS ↔ HCo [64]
SE RIA 21 MS levels within normalrange [142]
PL Luminescence 64 MS (RR/SP/PP) progressive MS ↓ RR [143]
CSF/SE ELISA 21 CIS CIS ↓ Co∗∗ [105]
CSF Immunoluminometry 33MS (RR/SP) RR ↔ SP [144]
REF: reference; APP: amyloid-precursor protein; NAA: N-acetylaspartate; NSE: neuron-speciﬁc enolase; SE: serum; PL: plasma; ELISA: Enzyme-Linked
Immunosorbent Assay; t-t: total tau protein, p-t: abnormally phosphorylated tau protein; xMAP: xMap Bead-based immunoassay; SELDI-TOF: Surface-
Enhanced Laser Desorption/Ionization Time-Of-Flight; GC-MS: stable isotope dilution gas chromatography-mass spectrometry; RIA: radioimmunoassay;
RR: relapsing-remittingMS; SP: secondary-progressive MS; PP: primary-progressive MS; ↑↑signiﬁcantlyhigherthan; ↓↓signiﬁcantlylowerthan;↓lowerthan;
↔ no diﬀerence between; OIND: other inﬂammatory neurological diseases; NIND: noninﬂammatory neurological disorders; Co: controls with ∗idiopathic
headache, Bell’s palsy and ischialgiaor ∗∗idiopathic headache and migraine; NHCo: neurologically healthy controls; OND: other neurological diseases;HCo:
healthy controls.Multiple Sclerosis International 9
(MSFC) (Table 2), although these levels were similar to
controls both in MS [141] and early MS patients [54].
CSF NAA levels were shown to be lower in SPMS patients
compared to RR and PPMS cases [54, 141]( T a b l e4).
Teunissen et al. reported a decrease in CSF NAA levels as
the disease progressed, therefore possibly reﬂecting the
accumulationofaxonaldegenerationinalaterMSstage[54].
One study has shown CSF NAA concentrations to correlate
with age [54].
3.9. Apolipoprotein E. Apolipoprotein E (Apo-E) is mostly
produced by astrocytes in the CNS, but it is also found in
neurons [21]. There are three diﬀerent alleles of the human
Apo-E gene coding for the three isoforms: ε2, ε3, and ε4
[145]. Apo-E is generally involved in lipid transport and
cholesterol homeostasis [21]. However, its functions within
the CNS are not so clear and might include immunomodu-
lation, a protective role against oxidative stress [146], a role
in maintaining the BBB integrity [147], a role in myelin
lipid metabolism [148], and a potential role in neurorepair
[21]. As there is a limited permeability of Apo- E across the
BBB, Apo- E changes in CSF might dominantly result from a
reduction of its local synthesis and secretion by brain tissue
[146, 149].
Several studies have indicated that Apo-E ε4 allele
might be associated with MS, although evidence is still not
suﬃcient enough [146, 150]. Although plausible [151], the
association between Apo-E and MS course and disease sever-
ityremainscontroversial[152].Apo-Egenotypesseemnotto
inﬂuence the development of MS, but Apo-E ε4 allele might
predispose carriers with MS to a faster disease progression
[153, 154]. In line with this, lower levels of NAA in MS
patients with the Apo-E ε4 allele have been demonstrated
by MRS [155]. It has been recently suggested that Apo-
E polymorphism may interact with cigarette smoking in
promoting MS progression [156]. Although some authors
h a v es h o w na na s s o c i a t i o nb e t w e e nA p o - Eε4a n dc o g n i t i v e
impairment in MS patients [157], the others could not
conﬁrm this ﬁnding [158].
However, it was suggested that the decreased CSF Apo-E
concentration in MS patients occurs independent of the
Apo-E genotype [159]. In one study the plasma concen-
tration of Apo-E was signiﬁcantly lower in MS patients
than in healthy controls although its CSF concentrations
were similar in these two groups [148]. Rifai et al. have
shownhigherCSF/serumApo-EindexinRRMSinremission
compared to controls [160], Chiasserini et al. demonstrated
an increased CSF expression of an Apo-E isoform in RRMS
compared to CISpatientsor controls[161], whereas Gaillard
et al. [159] found lower concentrations of both CSF Apo-E
and intrathecal Apo-E in MS patients than in controls
(Table 5). No correlation of Apo-E in serum or CSF with age
or clinical course was found [159].
3.10. Neuron-Speciﬁc Enolase. Enolase is a glycolytic enzyme
(2-phospho-D-glycerate hydrolase), which exists in three
isoforms: α-enolase, which is ubiquitous, β-enolase, which
is predominant in muscle, and γ-enolase (neuron-speciﬁc
enolase, NSE), which is found in neurons, glial, and neu-
roendocrine cells [84]. NSE was shown to be an indicator
of the acute neuro-destructive disorders [162], but its levels
are usually normal in MS patients [162] and no clear
diﬀerence in the NSE levels has been observed between
MS patients and controls in CSF [64]o rs e r u m[ 142], or
between patients with RR and SPMS in CSF [144]( T a b l e4).
NSE concentration in CSF and serum was shown to be
decreased in CIS patients when compared to the control
group, potentially indicating a reduced neuronal metabolic
activity at the early stage of the disease [105]. Interestingly,
Forooghian et al. demonstrated a higher T-cell responses
against NSE in the peripheral blood mononuclear cells of MS
patients than in controls [84]. One study which followed
CSF NSE levels in MS patients treated with intrathecal
triamcinolone administration did not show any changes in
its levelsfollowing treatment [163]. A recent study examined
plasma NSE levels in MS patients over a ﬁve-year period
and found a strong inverse relationship between serum NSE
levels and disease progression [143] as expressed through
EDSS and MSSS score changes, thus potentially reﬂecting a
reduced metabolic activity secondary to axonal loss. In two
other studies no correlation of CSF [64, 105]o rs e r u m[ 105]
NSE levels were found with EDSS (Table 2). Age-related
changes of NSE in CSF with an increase of 1% per year have
been reported [164], but in some other studies CSF NSE
levels were independent of gender, age [64, 165], and disease
duration [64].
3.11. Growth-Associated Protein 43. Growth-associated pro-
tein 43 (GAP-43), also known as B-50 or neuromodulin, is
a marker associated with growth cones, synaptic plasticity,
and synaptic regeneration [166]. It is a calmodulin-binding
protein being attached to the cytoplasmic site of the axonal
membrane, involvedinneurotransmitter release [167]w h i c h
alsostimulatesneuriteoutgrowth[166].AdecreasedGAP-43
expression was found in postmortem white matter MS
lesions, independent of the lesion stage, whereas increased
or unaltered expression was detected in remyelinated lesions
and was found unchanged in grey matter lesions [167].
In a recent study, CSF GAP-43 levels were comparable
among RR/SP and PPMS subtypes and controls and GAP-
43 was not detected in serum [167]( T a b l e5). A tendency
towards a negative correlation between CSF GAP-43 levels
and EDSS was found, but CSF GAP 43 levels positively
correlated with MRI measures of atrophy [167]( T a b l e2).
Moreover, a positive correlation was observed between CSF
NAAand GAP-43 levels[141].Nosigniﬁcant correlation was
reported between CSF GAP-43 levels and age, gender, and
disease duration [167].
3.12. 24S-Hydroxycholesterol. Cholesterol plays a crucial
structural role in the brain [168] being the main lipid of
neuronal membranes [21]. For maintenance of brain choles-
terolhomeostasis[168],cholesterolisconvertedintoitsmore
polar metabolitecerebrosterol (24S-hydroxycholesterol,24S-
OH-chol) by the CNS-speciﬁc cytochrome P450 enzyme
CYP46 [169]. Virtually all of the cerebrosterol in the10 Multiple Sclerosis International
Table 5: Membrane and nuclear biomarkers of neuroaxonal damage in the cerebrospinal ﬂuid (CSF) and blood of patients with multiple
sclerosis (MS) and/or clinically isolated syndrome suggestive of MS (CIS).
Biomarker
(subtype) Body ﬂuid Immunoassay Number of patients Main ﬁndings REF
BACE1
(membrane) CSF Enzymatic 100 MS (RR/SP/PP) MS slightly↓NHCo [122]
Apo-E
(membrane)
CSF/SE Immunoﬂuorometry 34 MS CSF levels in MS ↓↓ NHCo [159]
CSF 2DE-MS 10 RRMS + 11 CIS one isoform expression in RR ↑↑
CIS or NHCo [161]
CSF/SE Immunoturbidimetry 33 MS (RR) CSF/serum index in MS in
remission ↑↑ NHCo [160]
GAP-43
(membrane)
CSF/SE xMap Bead –based 49 MS (RR/SP/PP)
CSF in RR ↔ SP ↔ PP ↔ OIND
+ NIND + HCo, not detected in
serum
[167]
CSF xMap Bead –based 44 MS (RR/SP/PP) signiﬁcant positive correlation
with NAA levels [141]
24S-OH-chol
(membrane)
PL IDMS 46 MS (RR/PP) negative correlation with T2
lesion volume [169]
PL IDMS 11 MS MS ↔ HCo [170]
CSF/PL IDMS 118 MS (RR/SP/PP) PL levels in older MS ↓↓ HCo [171]
SE IDMS 60 MS (RR/SP/PP) PP or older RR ↓ HCo [172]
CSF/PL IDMS 88 MS PL levels in MS ↔ Co [173]
Protein 14-3-3
(cytoplasmic, nuclear,
membrane)
CSF Western blot 22 MS (RR/SP/PP) +
15 ATM
detected in about 8% RR/ATM
patients [174]
CSF Immunoblot 38 CIS detected in 13% CIS patients [175]
CSF/SE Immunoblot 21 CIS detected in 1/21 patient [105]
CSF ELISA 114 MS (RR/SP/PP) detected in 22% MS patients, not
detected in HCo [108]
CSF Immunoblot
43 MS
(RR/SP/PP/PR) + 20
CIS
detected in 38% CIS/MS, similar
in MS subgroups [140]
CSF Immunoblot 85 CIS detected in 8.2 % CIS patients [176]
REF: reference; BACE1: β-siteamyloidprecursor protein-cleaving enzyme1; Apo-E: Apolipoprotein-E; GAP-43:growth-associated protein-43; 24S-OH-chol:
2 4 S - h y d r o x y c h o l e s t e r o l ;S E :s e r u m ;P L :p l a s m a ;E n z y m a t i c :E n z y m a t i cs o l u tion-based assay; 2DE-MS: two-dimensional electrophoresis-mass spectrometry;
IDMS: isotope-dilution mass spectrometry; ELISA: Enzyme-Linked Immunosorbent Assay; RR: relapsing-remitting MS; SP: secondary-progressive MS;P P :
primary-progressive MS; ATM: acute transverse myelitis; NAA: N-acetylaspartate; ↓ lower than; ↓↓ signiﬁcantly lower than; ↑↑ signiﬁcantly higher than;
↔ no diﬀerence between; NHCo: neurologically healthy controls; OIND: other inﬂammatory neurological diseases; NIND: noninﬂammatory neurological
disorders; HCo: healthy controls; Co: controls with idiopathic headache.
peripheral circulation is CNS derived and its blood levels
are assumed to reﬂect the relation between cholesterol CNS
production caused by demyelination or neurodegeneration
and hepatic clearance [170, 177, 178]. The level of 24S-
OH-chol highly correlated with total cholesterol and the
ratio between 24S-OH-chol and cholesterol is assumed to
be a better marker for the cerebral production than the
absolute cerebrosterol concentration [171]. The majority of
daily eﬄux of this oxysterol from the brain to the circulation
apparently occurs as a direct transport across the BBB and
less than 1% of the total ﬂux of 24S-OH-chol from the
brain occurs via CSF [168], which might cause the lack of
correlation between CSF and plasma levels of this metabolite
[171].
The higher CSF levels of 24S-OH-chol were shown in
patients with gadolinium-enhancing MRI lesions, indicating
the pronounced release of the 24S-OH-chol from damaged
cells during CNS inﬂammation [171, 173]( T a b l e2). More-
over, patients with a defective BBB were found to have
markedly increased absolute levels of 24-OH-chol in CSF
[179]. Karrenbauer et al. [169]d e m o n s t r a t e dan e g a t i v e
correlation between the cerebrosterol/cholesterol ratio in
plasma and volume of T2-weighted MRI lesions, whereas
a signiﬁcant inverse relation between the EDSS score and
plasma cholesterol-related levels of 24S-OH-chol was found
in the other study [171]. Teunissen et al. [172]s h o w e d
the reduction in serum 24S-OH-chol concentrations to be
most pronounced in the PP clinical subtype (Table 5).
Leoni et al. found a tendency to increased plasma levels of
24S-OH-chol in younger patients with high levels in the
3rd and 4th decades of life, and signiﬁcantly lower levels
in older MS patients aged 51–70 years than in healthy
age-matched controls [171]. There seems to be no gender
inﬂuence on plasma levels of 24S-OH-chol or the ratioMultiple Sclerosis International 11
between cerebrosterol/cholesterol [171] and no correlation
of the latter with disease duration was reported to date
[172].
3.13. Protein 14-3-3. 14-3-3 family proteins are ubiquitous,
highly conserved proteins with the highest concentrations in
brain [162, 180] and within CNSare constitutivelyexpressed
in neurons and glia both in cytoplasmic and nuclear regions
[181] with small amounts bound to synaptic membranes
[162]. A growing body of evidence indicates that it might act
as a novel type of molecular chaperone which interacts with
key molecules involved in cell diﬀerentiation, proliferation,
and transformation [182], and recent data suggested its
antiapoptotic eﬀects [183, 184]. The detection of 14-3-3
protein in the CSF is highly sensitive for in vivo diagnosis
of Creutzfeldt-Jakob disease [185], but this protein, in the
CSF, could be also detected in some other prion-unrelated
conditions associated with CNS tissue damage [175, 181,
186].
The 14-3-3 protein is more frequently detectable in the
CSF of MS or CIS patients than in controls although in such
cases it is present in a small subgroup of patients [108, 174].
However, in the study of Colucci et al. [140]i tw a sm o r e
frequently positive than previously reported (Table 5). The
detection of the 14-3-3 protein in the CSF of CIS patients
was shown to be an independent predictor of short-term
conversion to CDMS [175, 176]( T a b l e2). Moreover, the 14-
3-3 positive group had a signiﬁcantly higher relapse rate and
ahigherfrequencyofpatientswithEDSS≥2.0aftera median
followup of 33.4 months [176], which conﬁrmed previous
results by the same authors [175]. In some studies, 14-3-3
protein positivity in MS patients was associated with a more
severedisability[140,187]andtherateofdiseaseprogression
during a mean of 10-month clinical followup [140], but
was also shown to be a potential predictor of permanent
neurologicaldisabilityafteranepisodeoftheacutetransverse
myelitis [188]. However, the latter was not shown in two
other studies [115, 174]. The presence of 14-3-3 reactivity
was not shown to prevail in MS clinical subgroups [140]a n d
seems not to correlate with age [108] or disease duration
[140].
3.14. Proteomics Research. Recently, a rapid development of
proteomic approaches refocused biomarker research interest
to the use of novel methods in the discovery of potential
MS-speciﬁc biomarkers in biological ﬂuids and especially
in the CSF [189, 190]. Among the wide range of proteins
that have been found to be exclusively present in the CSF
of MS patients [125, 189, 191–194], only some of them
are expressed on neurons (contactin-1, neurofascin, neu-
rotrimin, and chromogranins/secretogranins) [193–195]. It
was recently shown that contactin-2 was recognised by both
autoantibodies and Th1/Th17 T-cells in MS patients [36, 37]
and neurofascin-speciﬁc autoantibodies were identiﬁed in
MS patients [196]. However, there is a range of neuroaxonal
proteins which still need to be studied in CIS/MS patients
although some of them have been investigated in animal
models [197].
4.Summary andFutureDirectives
Based onthe majority ofavailableresults, theincreased levels
of the CSF NF-L or NF-H seem to be present even at early
MS phases, a scenario which continues during the entire
course of the disease and correlates with diﬀerent measures
of disability; the increased levels of these markers seem to be
morepronouncedinactivediseasestatesandhaveapotential
v a l u ei na ne ﬀort to predict conversion to CDMS after a
ﬁrst CIS episode, estimate future progression and disability,
but their value for the prediction of treatment response
still has to be investigated, most importantly in early MS
patients.
Although the presence of anti-NF antibodies could, in
part, be an epiphenomenon of the disease, the elevated levels
of these antibodies in progressive disease and correlations
with disease duration and disability indicate a rise in
antibodies induced by axonal destruction, but also a possible
pathogenic role of these antibodies in promoting axonal
damage and disease progression. This indicates that serum
and/or CSF anti-NF-L, NF-M, and NF-H antibodies might
be a potential a marker of CNS tissue damage in MS, but
their potential predictive value for the future disease course,
disability, disease progression, and treatment response needs
to be investigated.
CSF levels of actin and tubulin seem to be elevated in
progressive MS and correlate with disability, but their levels
in early MS patients, as well as the potential predictive value
have been underreported to date.
It is possible that elevated CSF t-tau levels are present
from early MS phases and increase in clinically/MRI active
disease phases; although its potential correlation with ongo-
ing disease progression has been indicated, the reports
related to this molecule so far have been quite contradictory
and its validity as a biomarker needs to be further studied
both in blood and CSF.
CSF and blood levels of APP-derived proteins seem not
to be reliable markers of disease activity or progression since
their levels are largely dependent on complex regulatory
metabolic processes which could be highly variable in a
complex and heterogenous disease such as MS.
A correlation of CSF NAA levels with disability mea-
sures even in CIS patients suggests the potential clinical
relevance of this molecule as a biomarker that should be
further investigated.
NSE and Apo-E levels in CSF/blood are not consistently
abnormal in MS patients and their relation to neuroax-
onal damage is complicated since the expression of both
molecules is not limited to neurons.
CSF/blood levels of GAP-43 were investigated to date
in a paucity of studies and some preliminary results might
indicate the need for further investigations of this molecule
as of the potential biomarker of disease progression and
disability.
Serum 24S-OH-chol levels seem to be as reliable as levels
in CSF to estimate neuronal membrane status. Some reports
indicated its correlation with disability and MS disease
activity and thus the validity of this molecule as a biomarker
should be further investigated.12 Multiple Sclerosis International
The 14-3-3 family proteins could be potentially related
to CIS conversion to MS, disability, and its progression, but
this still has to be further conﬁrmed. Astrocyte-derived 14-
3-3 protein couldcomplicatethe relation ofCSF/bloodlevels
of 14-3-3 protein only to neuroaxonal status in MS.
Additionally, it would be desirable to systematically
compare the proteome proﬁles of MS subgroups at a deﬁned
disease stages and in large cohorts in order to identify
proteinswhich areconsistentlypresentintheCSFatacertain
disease phase in a given subgroup, a task which is still facing
a lot of obstacles.
So far, the abovementioned markers have been investi-
gated in the light of their signiﬁcance to reﬂect the presence
and the extent of neuroaxonal damage in CIS/MS patients.
Sinceeachofthemcouldberelatedtodiﬀerentstructurallev-
els of neuroaxonal loss of integrity, the combined evaluation
of these markers could be more informative on the ongoing
neurodegenerative process [54]. Moreover, the relevance of
the single biomarker has to be judged in the light of disease
stage and/or disease activity since biomarker levels could
show temporal dynamics that correlates with the dynamics
of the MS natural course [54, 198].
The results of the biomarker studies could have been
inﬂuenced by small study sizes, cross-sectional designs, and
insuﬃcient followup to allow meaningful conclusions [199].
Biomarker studies in MS neurodegeneration have been
conducted in a variable patient population, varying from a
few [68] to over a hundred patients included [108, 171].
Moreover, followup in most of these studies was up to three
years [54, 62, 113, 140, 175, 176] which could allow only
tentative conclusions on biomarker’s long-term prognostic
signiﬁcance. The diﬀerences in preanalytical processes and
diﬀerent assay sensitivities could also cause contradictory
results in biomarker studies [199]. The comparable results
were shown in several studies that used the same NF-H
Enzyme-LinkedImmunosorbent Assay(ELISA)method[62,
70–72]. However, a poor interlaboratory coeﬃcient of vari-
ation in a recent multicenter NF-L ELISA validation study
has been shown, mainly due to the lack of preparation of
accurate and consistent protein standards [200]. Therefore,
a standardization of body ﬂuid sampling and storage [201],
as well as the use of the standardized and validated assay
procedures [23, 200], are needed.
Since none of the potential CSF/blood biomarkers stud-
ied so far fulﬁls all necessary criteria for a surrogate bio-
marker [22] there is an ongoing need for further biomarker
studies, especially those aiming to predict future disease
course, disability, and/or treatment response at the early MS
stage.
ConﬂictofInterests
There is no conﬂict of interests to declare.
Acknowledgment
This work was supported by a Grant from the Ministry of
Science and Technological Development of the Republic of
Serbia (Grant no. 175031).
References
[ 1 ]F .B a r k h o f ,P .A .C a l a b r e s i ,D .H .M i l l e r ,a n dS .C .R e i n g o l d ,
“Imaging outcomes for neuroprotection and repair in mul-
tiple sclerosis trials,” Nature Reviews Neurology,v o l .5 ,n o .5 ,
pp. 256–266, 2009.
[ 2 ]E .M .F r o h m a n ,M .F i l i p p i ,O .S t u v ee ta l . ,“ C h a r a c t e r i z i n g
themechanismsofprogressioninmultiplesclerosis:evidence
and new hypotheses for future directions,” Archives of
Neurology, vol. 62, no. 9, pp. 1345–1356, 2005.
[3] J.M.Charcot,Leconssurlesmaladies dusystemenerveuxfaites
al aS a l p e t r i e r e , A. Delahaye, Paris, France, 1880.
[ 4 ]N .A .L o s s e ﬀ,S .L .W e b b ,J .I .O ’ R i o r d a ne ta l . ,“ S p i n a l
cord atrophy and disability in multiple sclerosis. A new
reproducible and sensitive MRI method with potential to
monitor disease progression,” Brain, vol. 119, no. 3, pp. 701–
708, 1996.
[5] N. A. Losseﬀ,L .W a n g ,H .M .L a ie ta l . ,“ P r o g r e s s i v ec e r e b r a l
atrophy in multiple sclerosis. A serial MRI study,” Brain,v o l .
119, no. 6, pp. 2009–2019, 1996.
[6] B .D .T rap p ,J .P e t e r son,R .M.R ansohoﬀ,R.R udick,S.M¨ ork,
and L. B¨ o, “Axonal transection in the lesions of multiple
sclerosis,” New England Journal of Medicine, vol. 338, no. 5,
pp. 278–285, 1998.
[ 7 ]B .D .T r a p p ,R .R a n s o h o ﬀ,and R. Rudick, “Axonal pathology
in multiple sclerosis: relationship to neurologic disability,”
Current Opinion in Neurology, vol. 12, no. 3, pp. 295–302,
1999.
[8] C. Bjartmar, G. Kidd, S. M¨ ork, R. Rudick, and B. D. Trapp,
“Neurological disability correlates with spinal cord axonal
loss and reduced N-acetyl aspartate in chronic multiple
sclerosis patients,” Annals of Neurology,v o l .4 8 ,n o .6 ,p p .
893–901, 2000.
[ 9 ]B .D .T r a p pa n dK .A .N a v e ,“ M u l t i p l es c l e r o s i s :a ni m m u n e
or neurodegenerative disorder?” Annual Review of Neuro-
science, vol. 31, pp. 247–269, 2008.
[ 1 0 ]B .F e r g u s o n ,M .K .M a t y s z a k ,M .M .E s i r i ,a n dV .H .P e r r y ,
“Axonal damage in acute multiple sclerosis lesions,” Brain,
vol. 120, no. 3, pp. 393–399, 1997.
[ 1 1 ]J .W .P e t e r s o n ,L .B ¨ o, S. M¨ ork, A. Chang, and B. D.
Trapp, “Transected neurites, apoptotic neurons, and reduced
inﬂammationin cortical multiple sclerosislesions,”Annals of
Neurology, vol. 50, no. 3, pp. 389–400, 2001.
[ 1 2 ]R .H u i z i n g a ,W .G e r r i t s e n ,N .H e i j m a n s ,a n dS .A m o r ,
“Axonal loss and gray matter pathology as a direct result of
autoimmunity to neuroﬁlaments,” Neurobiology of Disease,
vol. 32, no. 3, pp. 461–470, 2008.
[13] M. Vercellino, S. Masera, M. Lorenzatti et al., “Demyeli-
nation, inﬂammation, and neurodegeneration in multiple
sclerosis deep gray matter,” Journal of Neuropathology and
Experimental Neurology, vol. 68, no. 5, pp. 489–502, 2009.
[14] D. H. Miller, A. J. Thompson, and M. Filippi, “Magnetic
resonance studies of abnormalities in the normal appearing
white matterandgrey matterin multiplesclerosis,”Journal of
Neurology, vol. 250, no. 12, pp. 1407–1419, 2003.
[ 1 5 ]A .C e c c a r e l l i ,M .A .R o c c a ,A .F a l i n ie ta l . ,“ N o r m a l -
appearing whiteandgreymatterdamageinMS:a volumetric
and diﬀusion tensor MRI study at 3.0 Tesla,” Journal of
Neurology, vol. 254, no. 4, pp. 513–518, 2007.
[16] F. Aboul-Enein, M. Krˇ sˇ s´ ak, R. H¨ oftberger, D. Prayer, and
W. Kristoferitsch, “Reduced NAA-Levels in the NAWM of
patients with MS is a feature of progression. A study with
quantitative magnetic resonance spectroscopy at 3 Tesla,”
PLoS ONE, vol. 5, no. 7, article e11625, 2010.Multiple Sclerosis International 13
[17] C. Bjartmar and B. D. Trapp, “Axonal and neuronal degen-
eration in multiple sclerosis: mechanisms and functional
consequences,” Current Opinion in Neurology,v o l .1 4 ,n o .3 ,
pp. 271–278, 2001.
[18] C. Bjartmar, J. R. Wujek, and B. D. Trapp, “Axonal loss in
the pathology of MS: consequences for understanding the
progressive phase of the disease,” Journal of the Neurological
Sciences, vol. 206, no. 2, pp. 165–171, 2003.
[19] R. Dutta and B. D. Trapp, “Pathogenesis of axonal and
neuronal damage in multiple sclerosis,” Neurology, vol. 68,
no. 22, supplement, pp. S22–S31, 2007.
[20] G. Giovannoni, A. J. E. Green, and E. J. Thompson, “Are
there any body ﬂuid markers of brain atrophy in multiple
sclerosis?”Multiple Sclerosis, vol. 4, no. 3, pp. 138–142, 1998.
[21] C. E. Teunissen, P. C. Dijkstra, and C. Polman, “Biological
markers in CSF and blood for axonal degeneration in multi-
ple sclerosis,”LancetNeurology, vol.4, no.1,pp. 32–41,2005.
[22] B. Bielekova and R. Martin, “Development of biomarkers
in multiple sclerosis,” Brain, vol. 127, no. 7, pp. 1463–1478,
2004.
[23] J. Kuhle, A. Regeniter, D. Leppert et al., “A highly sensitive
electrochemiluminescence immunoassay for the neuroﬁla-
ment heavy chain protein,” Journal of Neuroimmunology,v o l .
220, no. 1-2, pp. 114–119, 2010.
[24] A. Van der Walt, H. Butzkueven, S. Kolbe et al., “Neuropro-
tection in multiple sclerosis: a therapeutic challenge for the
next decade,” Pharmacology and Therapeutics, vol. 126, no. 1,
pp. 82–93, 2010.
[ 2 5 ]J .B r e t t s c h n e i d e r ,A .P e t z o l d ,A .J u n k e r ,a n dH .T u m a n i ,
“Axonal damage markers in the cerebrospinal ﬂuid of
patientswithclinicallyisolatedsyndromeimprovepredicting
conversion to deﬁnite multiple sclerosis,” Multiple Sclerosis,
vol. 12, no. 2, pp. 143–148, 2006.
[26] A. Lutterotti, T. Berger, and M. Reindl, “Biological markers
for multiple sclerosis,” Current Medicinal Chemistry,v o l .1 4 ,
no. 18, pp. 1956–1965, 2007.
[ 2 7 ]M .C o m a b e l l a ,M .F e r n ´ andez, R. Martin et al., “Cere-
brospinal ﬂuid chitinase 3-like 1 levels are associated with
conversion to multiple sclerosis,” Brain, vol. 133, no. 4, pp.
1082–1093, 2010.
[28] J. L. Jones and A. J. Coles, “Campath-1H treatment of mul-
tiple sclerosis,” Neurodegenerative Diseases,v o l .5 ,n o .1 ,p p .
27–31, 2007.
[29] H. Wiendl and R. Hohlfeld, “Multiple sclerosis therapeutics:
unexpected outcomes clouding undisputed successes,” Neu-
rology, vol. 72, no. 11, pp. 1008–1015, 2009.
[30] E. Leray, J. Yaouanq, E. Le Page et al., “Evidence for a two-
stage disability progression in multiple sclerosis,” Brain,v o l .
133, no. 7, pp. 1900–1913, 2010.
[31] M. Daumer, A. Neuhaus, S. Morrissey, R. Hintzen, and G.
C. Ebers, “MRI as an outcome in multiple sclerosis clinical
trials,” Neurology, vol. 72, no. 8, pp. 705–711, 2009.
[ 3 2 ]L .B ø ,C .A .V e d e l e r ,H .N y l a n d ,B .D .T r a p p ,a n dS .J .M ø r k ,
“Intracortical multiple sclerosis lesions are not associated
with increased lymphocyte inﬁltration,” Multiple Sclerosis,
vol. 9, no. 4, pp. 323–331, 2003.
[33] J. M. Frischer, S. Bramow,A. Dal-Bianco et al., “The relation
between inﬂammation and neurodegeneration in multiple
sclerosis brains,” Brain, vol. 132, no. 5, pp. 1175–1189, 2009.
[34] H. Lassmann, “What drives disease in multiple sclerosis:
inﬂammation or neurodegeneration?” Clinical and Experi-
mental Neuroimmunology, vol. 1, pp. 2–11, 2010.
[35] E. Silber and M. K. Sharief, “Axonal degeneration in the
pathogenesisofmultiplesclerosis,”JournaloftheNeurological
Sciences, vol. 170, no. 1, pp. 11–18, 1999.
[36] T. Derfuss, K. Parikh, S. Velhin et al., “Contactin-2/TAG-
1-directed autoimmunity is identiﬁed in multiple sclerosis
patients and mediates gray matter pathology in animals,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 106, no. 20, pp. 8302–8307, 2009.
[37] T. Derfuss, C. Linington, R. Hohlfeld, and E. Meinl, “Axo-
glial antigens as targets in multiple sclerosis: implications for
axonalandgreymatterinjury,”JournalofMolecularMedicine,
vol. 88, no. 8, pp. 753–761, 2010.
[38] H. Neumann, I. M. Medana, J. Bauer, and H. Lassmann,
“Cytotoxic T lymphocytes in autoimmune and degenerative
CNSdiseases,”TrendsinNeurosciences,vol.25,no.6,pp.313–
319, 2002.
[39] L. H. Kasper and J.Shoemaker,“Multiple sclerosisimmunol-
ogy: the healthy immune system vs the MS immune system,”
Neurology, vol. 74, pp. S2–S8, 2010.
[ 4 0 ]K .K i e r d o r f ,Y .W a n g ,a n dH .N e u m a n n ,“ I m m u n e - m e d i a t e d
CNS damage,” Results and Problems in Cell Diﬀerentiation,
vol. 51, pp. 173–196, 2010.
[41] D. O. Willenborg, M. A. Staykova, and W. B. Cowden, “Our
shifting understanding of the role of nitric oxide in autoim-
mune encephalomyelitis: a review,” Journal of Neuroim-
munology, vol. 100, no. 1-2, pp. 21–35, 1999.
[42] G. C. Brown and V. Borutaite, “Nitric oxide inhibition of
mitochondrial respiration and its role in cell death,” Free
Radical Biology and Medicine, vol. 33, no. 11, pp. 1440–1450,
2002.
[43] R. E. Gonsette, “Neurodegeneration in multiple sclerosis:
the role of oxidative stress and excitotoxicity,” Journal of the
Neurological Sciences, vol. 274, no. 1-2, pp. 48–53, 2008.
[44] P. Werner, D. Pitt, and C. S. Raine, “Glutamate excitotoxic-
ity—a mechanism for axonal damage and oligodendrocyte
death in multiple sclerosis?” J o u r n a lo fN e u r a lT r a n s m i s s i o n ,
no. 60, pp. 375–385, 2000.
[45] G. Lazzarino,A.M.Amorini,M.J.Eikelenboomet al.,“Cere-
brospinal ﬂuid ATP metabolites in multiple sclerosis,” Multi-
ple Sclerosis, vol. 16, no. 5, pp. 549–554, 2010.
[46] D. Mahad, H. Lassmann, and D. Turnbull, “Review: mito-
chondria and disease progression in multiple sclerosis,” Neu-
ropathology and Applied Neurobiology, vol.34,no.6,pp. 577–
589, 2008.
[47] T. Owens, “The enigma of multiple sclerosis: inﬂammation
and neurodegeneration cause heterogeneous dysfunction
and damage,” Current Opinion in Neurology, vol. 16, no. 3,
pp. 259–265, 2003.
[48] S. G. Waxman, M. J. Craner, and J. A. Black, “Na+ channel
expression along axons in multiple sclerosis and its models,”
Trends in Pharmacological Sciences, vol. 25, no. 11, pp. 584–
591, 2004.
[ 4 9 ]M .N .R a s b a n d ,J .T a y l e r ,Y .K a g ae ta l . ,“ C N Pi sr e q u i r e df o r
maintenance of axon-glia interactions at nodes of ranvier in
the CNS,” GLIA, vol. 50, no. 1, pp. 86–90, 2005.
[50] O. W. Howell, J. L. Rundle, A. Garg, M. Komada, P.
J. Brophy, and R. Reynolds, “Activated microglia mediate
axoglial disruption that contributes to axonal injury in mul-
tiple sclerosis,” Journal of Neuropathology and Experimental
Neurology, vol. 69, no. 10, pp. 1017–1033, 2010.
[ 5 1 ]S .P e t r a t o s ,M .F .A z a r i ,E .O z t u r k ,R .P a p a d o p o u l o s ,a n d
C. C. A. Bernard, “Novel therapeutic targets for axonal
degenerationinmultiplesclerosis,”JournalofNeuropathology14 Multiple Sclerosis International
and Experimental Neurology, vol. 69, no. 4, pp. 323–334,
2010.
[52] Y. Yang, Y. Liu, P. Wei et al., “Silencing Nogo—a promotes
functional recovery in demyelinating disease,” Annals of
Neurology, vol. 67, no. 4, pp. 498–507, 2010.
[53] P .Sp it z e r ,H .W .K laf ki,K .Ble nno we tal. ,“ C N E U PR O:no v e l
biomarkers for neurodegenerative diseases,” International
Journal of Alzheimer’s Disease, vol. 2010, Article ID 548145,
12 pages, 2010.
[54] C. E. Teunissen, E. Iacobaeus, M. Khademi et al., “Combina-
tionofCSFN-acetylaspartate andneuroﬁlamentsinmultiple
sclerosis,”Neurology, vol. 72, no. 15, pp. 1322–1329, 2009.
[55] M. K. Lee and D. W. Cleveland, “Neuronal intermediate
ﬁlaments,” Annual Review of Neuroscience, vol. 19, pp. 187–
217, 1996.
[56] M. M. Gresle, G. Shaw, B. Jarrott et al., “Validation of a
novel biomarker for acute axonal injury in experimental
autoimmune encephalomyelitis,” Journal of Neuroscience
Research, vol. 86, no. 16, pp. 3548–3555, 2008.
[57] A. Petzold, “Neuroﬁlament phosphoforms: surrogate mark-
ers for axonal injury, degeneration and loss,” Journal of the
Neurological Sciences,vol. 233, no. 1-2, pp. 183–198, 2005.
[58] M. E. Goldstein, N. H. Sternberger, and L. A. Sternberger,
“Phosphorylation protects neuroﬁlaments against proteoly-
sis,”Journal of Neuroimmunology, vol. 14, no. 2, pp. 149–160,
1987.
[59] J. P. Julien and W. E. Mushynski, “Neuroﬁlaments in health
and disease,” Progress in Nucleic Acid Research and Molecular
Biology, vol. 61, pp. 1–23, 1998.
[60] E. Fuchs and D. W. Cleveland, “A structural scaﬀolding of
intermediate ﬁlaments in health and disease,” Science,v o l .
279, no. 5350, pp. 514–519, 1998.
[61] J. N. Lycke, J. E. Karlsson, O. Andersen, and L. E. Rosengren,
“Neuroﬁlament protein in cerebrospinal ﬂuid: a potential
marker of activity in multiple sclerosis,” Journal of Neurology
Neurosurgery and Psychiatry, vol. 64, no. 3, pp. 402–404,
1998.
[62] A. Petzold, M. J.Eikelenboom,G. Keir et al., “Axonaldamage
accumulates in the progressive phase of multiple sclerosis:
three year follow up study,” Journal of Neurology, Neuro-
surgery and Psychiatry, vol. 76, no. 2, pp. 206–211, 2005.
[63] Y. K. Semra, O. A. Seidi, and M. K. Sharief, “Heightened
intrathecal release of axonal cytoskeletal proteins in multiple
sclerosis is associated with progressive disease and clinical
disability,” Journal of Neuroimmunology, vol.122,no.1-2, pp.
132–139, 2002.
[64] C.Malmestr¨ om,S.Haghighi,L.Rosengren,O.Andersen,and
J. Lycke, “Neuroﬁlament light protein and glial ﬁbrillary
acidic protein as biological markers in MS,” Neurology,v o l .
61, no. 12, pp. 1720–1725, 2003.
[65] N. Norgren, P. Sundstr¨ om, A. Svenningsson, L. Rosengren,
T. Stigbrand, and M. Gunnarsson, “Neuroﬁlament and glial
ﬁbrillary acidic protein in multiple sclerosis,” Neurology,v o l .
63, no. 9, pp. 1586–1590, 2004.
[ 6 6 ]M .J .E i k e l e n b o o m ,A .P e t z o l d ,R .H .C .L a z e r o ne ta l . ,
“Multiple sclerosis: neuroﬁlament light chain antibodies are
correlated to cerebral atrophy,” Neurology,v o l .6 0 ,n o .2 ,p p .
219–223, 2003.
[67] S. Haghighi, O. Andersen, A. Od´ en, and L. Rosengren,
“Cerebrospinal ﬂuid markers in MS patients and their
healthy siblings,” Acta Neurologica Scandinavica, vol.109, no.
2, pp. 97–99, 2004.
[68] L. E. Rosengren, J. E. Karlsson, J. O. Karlsson, L. I. Persson,
and C. Wikkelsø,“Patients with amyotrophic lateral sclerosis
and other neurodegenerative diseases have increased levels
of neuroﬁlament protein in CSF,” Journal of Neurochemistry,
vol. 67, no. 5, pp. 2013–2018, 1996.
[69] E. T. Lim,D. Grant, M.Pashenkovet al.,“Cerebrospinal ﬂuid
levels of brain speciﬁc proteins in optic neuritis,” Multiple
Sclerosis, vol. 10, no. 3, pp. 261–265, 2004.
[ 7 0 ]I .M i y a z a w a ,I .N a k a s h i m a ,A .P e t z o l d ,K .F u j i h a r a ,S .S a t o ,
and Y. Itoyama, “High CSF neuroﬁlament heavy chain levels
in neuromyelitis optica,” Neurology, vol. 68, no. 11, pp. 865–
867, 2007.
[71] A. Petzold, K. Rejdak, and G. T. Plant, “Axonal degenaration
and inﬂammation in acute optic neuritis,” Journal of Neu-
rology, Neurosurgery and Psychiatry, vol. 75, no. 8, pp. 1178–
1180, 2004.
[ 7 2 ]K .R e j d a k ,A .P e t z o l d ,Z .S t e l m a s i a k ,a n dG .G i o v a n n o n i ,
“Cerebrospinal ﬂuid brain speciﬁc proteins in relation to
nitric oxide metabolites during relapse of multiple sclerosis,”
Multiple Sclerosis, vol. 14, no. 1, pp. 59–66, 2008.
[73] N. Norgren, L. Rosengren, and T. Stigbrand, “Elevated neu-
roﬁlament levels in neurological diseases,” Brain Research,
vol. 987, no. 1, pp. 25–31, 2003.
[ 7 4 ]E .S i l b e r ,Y .K .S e m r a ,N .A .G r e g s o n ,a n dM .K .S h a r i e f ,
“Patients with progressive multiple sclerosis have elevated
antibodies to neuroﬁlament subunit,” Neurology, vol. 58, no.
9, pp. 1372–1381, 2002.
[75] J.Salzer,A.Svenningsson,andP.Sundstr¨ om,“Neuroﬁlament
light as a prognostic marker in multiple sclerosis,” Multiple
Sclerosis, vol. 16, no. 3, pp. 287–292, 2010.
[76] A. Petzold, M. J. Eikelenboom, G. Keir et al., “The new
globalmultiplesclerosisseverityscore(MSSS)correlateswith
axonal but not glial biomarkers,” Multiple Sclerosis, vol. 12,
no. 3, pp. 325–328, 2006.
[77] A. Petzold, D. Brassat, P. Mas et al., “Treatment response
in relation to inﬂammatory and axonal surrogate marker in
multiple sclerosis,” Multiple Sclerosis, vol. 10, no. 3, pp. 281–
283, 2004.
[78] E. T. Lim, F. Sellebjerg, C. V. Jensen et al., “Acute axonal
damage predicts clinical outcome in patients with multiple
sclerosis,”Multiple Sclerosis, vol.11,no.5, pp. 532–536,2005.
[79] A.Bartoˇ s,L.Fialov´ a,J.Soukupov´ a,J.Kukal,I.Malbohan,and
J. Piˇ tha, “Antibodies against light neuroﬁlaments in multiple
sclerosis patients,” Acta Neurologica Scandinavica, vol. 116,
no. 2, pp. 100–107, 2007.
[80] R. Ehling, A. Lutterotti, J. Wanschitz et al., “Increased fre-
quencies of serum antibodies to neuroﬁlament light in
patients withprimarychronicprogressive multiplesclerosis,”
Multiple Sclerosis, vol. 10, no. 6, pp. 601–606, 2004.
[81] L. Fialov´ a, A. Bartoˇ s, J. Soukupov´ a, J. ˇ Svarcov´ a, P. Ridzoˇ n,
and I. Malbohan, “Synergy of serum and cerebrospinal ﬂuid
antibodies against axonal cytoskeletal proteins in patients
with diﬀerent neurological diseases,” Folia Biologica, vol. 55,
no. 1, pp. 23–26, 2009.
[82] A. Bartoˇ s, L. Fialov´ a, J. Soukupov´ a, J. Kukal, I. Malbohan,
and J. Pit’ha, “Elevated intrathecal antibodies against the
mediumneuroﬁlamentsubunitinmultiplesclerosis,”Journal
of Neurology, vol. 254, no. 1, pp. 20–25, 2007.
[83] J. ˇ Svarcov´ a, L. Fialov´ a, A. Bartoˇ s, M. ˇ Steinbachov´ a, and I.
Malbohan, “Cerebrospinal ﬂuid antibodies to tubulin are
elevated in the patients with multiple sclerosis,” European
Journal of Neurology, vol. 15, no. 11, pp. 1173–1179, 2008.
[84] F. Forooghian, R. K. Cheung, W. C. Smith, P. O’Connor,
and H. M. Dosch, “Enolase and arrestin are novel non-
myelin autoantigens in multiple sclerosis,” Journal of Clinical
Immunology, vol. 27, no. 4, pp. 388–396, 2007.Multiple Sclerosis International 15
[85] D. B. Braxton, M. Williams, D. Kamali, S. Chin, R. Liem,
and N. Latov, “Speciﬁcity of human anti-neuroﬁlament
autoantibodies,” Journal of Neuroimmunology, vol. 21, no. 2-
3, pp. 193–203, 1989.
[86] B. O. Fabriek, J. N. P. Zwemmer, C. E. Teunissen et al., “In
vivo detection of myelin proteins in cervical lymph nodes of
MS patients using ultrasound-guided ﬁne-needle aspiration
cytology,” Journal of Neuroimmunology, vol. 161, no. 1-2, pp.
190–194, 2005.
[87] A. Prat and J. Antel, “Pathogenesis of multiple sclerosis,”
Current Opinion in Neurology, vol. 18, no. 3, pp. 225–230,
2005.
[88] K. Kamath, E. Oroudjev, and M. A. Jordan, “Determination
ofmicrotubuledynamicinstabilityinlivingcells,”Methodsin
Cell Biology, vol. 97, pp. 1–14, 2010.
[89] K. H. Downing, “Structural basis for the interaction of
tubulin with proteins and drugs that aﬀect microtubule
dynamics,” Annual Review of Cell and Developmental Biology,
vol. 16, pp. 89–111, 2000.
[90] N. B. Laferri` ere, T. H. MacRae, and D. L. Brown, “Tubulin
synthesis and assembly in diﬀerentiating neurons,” Biochem-
istry and Cell Biology, vol. 75, no. 2, pp. 103–117, 1997.
[91] D. Girard and J. L. Sen´ ecal, “Anti-microﬁlament IgG anti-
bodies in normal adults and in patients with autoim-
mune diseases: immunoﬂuorescence and immunoblotting
analysis of 201 subjects reveals polyreactivity with mi-
croﬁlament-associated proteins,” Clinical Immunology and
Immunopathology, vol. 74, no. 2, pp. 193–201, 1995.
[92] A. Kulakowska, W. Drozdowski, A. Sadzynski, R. Bucki, and
P. A. Janmey, “Gelsolin concentration in cerebrospinal ﬂuid
from patients with multiple sclerosis and other neurological
disorders,” European Journal of Neurology, vol. 15, no. 6, pp.
584–588, 2008.
[93] T. Paunio, H. Kangash, O. Heinonen et al., “Cells of the neu-
ronal lineage play a major role in the generation of amyloid
precursor fragments in gelsolin-related amyloidosis,”Journal
of Biological Chemistry, vol. 273, no. 26, pp. 16319–16324,
1998.
[ 9 4 ]H .L .Y i n ,D .J .K w i a t o k o w s k i ,J .E .M o l e ,a n dF .S .C o l e ,
“Structure and biosynthesis of cytoplasmic and secreted
variants of gelsolin,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 259,
no. 8, pp. 5271–5276, 1984.
[95] W. M. Lee and R. M. Galbraith, “The extracellular actin-
scavenger system and actin toxicity,” New England Journal of
Medicine, vol. 326, no. 20, pp. 1335–1341, 1992.
[96] A. Kułakowska, N. J. Ciccarelli, Q. Wen et al., “Hypogel-
solinemia, a disorder of the extracellular actin scavenger
system, in patients with multiple sclerosis,” BMC Neurology,
vol. 10, article 107, 2010.
[ 9 7 ]C .B a l l a t o r e ,V .M .Y .L e e ,a n dJ .Q .T r o j a n o w s k i ,“ T a u -
mediated neurodegeneration in Alzheimer’s disease and
related disorders,” Nature Reviews Neuroscience,v o l .8 ,n o .9 ,
pp. 663–672, 2007.
[98] G. V. W. Johnson and W. H. Stoothoﬀ,“Tau phosphorylation
in neuronal cell function and dysfunction,” Journal of Cell
Science, vol. 117, no. 24, pp. 5721–5729, 2004.
[99] B. Bandyopadhyay, G. Li, H. Yin, and J. Kuret, “Tau
aggregationandtoxicityinacell culturemodeloftauopathy,”
J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 282, no. 22, pp. 16454–
16464, 2007.
[100] J. M. Anderson, R. Patani, R. Reynolds et al., “Evidence for
abnormal tau phosphorylation in early aggressive multiple
sclerosis,”Acta Neuropathologica,vol.117,no.5,pp.583–589,
2009.
[101] J.M.Anderson,D.W.Hampton,R.Patanietal.,“Abnormally
phosphorylated tau is associated with neuronal and axonal
loss in experimental autoimmune encephalomyelitis and
multiple sclerosis,” Brain, vol. 131, no. 7, pp. 1736–1748,
2008.
[102] J. M. Anderson, R. Patani, R. Reynolds et al., “Abnormal tau
phosphorylation in primary progressive multiple sclerosis,”
Acta Neuropathologica, vol. 119, no. 5, pp. 591–600, 2010.
[103] J. Brettschneider, M. Maier, S. Arda et al., “Tau protein
level in cerebrospinal ﬂuid is increased in patients with early
multiple sclerosis,” Multiple Sclerosis, vol. 11, no. 3, pp. 261–
265, 2005.
[104] J.Guimar˜ aes,M.J.Cardoso,andM.J.S´ a,“Tau protein seems
not tobe auseful routine clinicalmarkerofaxonaldamagein
multiple sclerosis,” Multiple Sclerosis, vol. 12, no. 3, pp. 354–
356, 2006.
[105] K. Hein N´ ee Maier, A. K¨ ohler, R. Diem et al., “Biological
markers for axonal degeneration in CSF and blood of
patients with the ﬁrst event indicative for multiple sclerosis,”
Neuroscience Letters, vol. 436, no. 1, pp. 72–76, 2008.
[106] M. Valiˇ s, R. Tal´ ab, P. ˇ Sˇ touraˇ c, C. Andr´ ys, and J. Maso-
pust, “Tau protein, phosphorylated tau protein and beta-
amyloid42 in the cerebrospinal ﬂuid of multiple sclerosis
patients,” Neuroendocrinology Letters, vol. 29, no. 6, pp. 971–
976, 2008.
[107] E. Kapaki, G. P. Paraskevas, M. Michalopoulou, and K.
Kilidireas, “Increased cerebrospinal ﬂuid tau protein in
multiple sclerosis,” European Neurology,v o l .4 3 ,n o .4 ,p p .
228–232, 2000.
[108] H. Bartosik-Psujek and J. J. Archelos, “Tau protein and 14-
3-3 are elevated in the cerebrospinal ﬂuid of patients with
multiple sclerosis and correlate with intrathecal synthesis of
IgG,” Journal of Neurology, vol.251, no.4, pp. 414–420,2004.
[109] H. Bartosik-Psujek and Z. Stelmasiak, “The CSF levels
of total-tau and phosphotau in patients with relapsing-
remitting multiple sclerosis,” Journal of Neural Transmission,
vol. 113, no. 3, pp. 339–345, 2006.
[110] M. Terzi, A. Birinci, E. C ¸etinkaya, and M. K. Onar, “Cere-
brospinal ﬂuid total tau protein levels in patients with
multiple sclerosis,” Acta Neurologica Scandinavica, vol. 115,
no. 5, pp. 325–330, 2007.
[111] F. J. Jim´ enez-Jim´ enez, J. M. Zurdo, A. Hernanz et al., “Tau
protein concentrations incerebrospinal ﬂuid ofpatients with
multiple sclerosis,” Acta Neurologica Scandinavica, vol. 106,
no. 6, pp. 351–354, 2002.
[112] K. Rostasy, E. Withut, D. Pohl et al., “Tau, phospho-tau, and
S-100B in the cerebrospinal ﬂuid of children with multiple
sclerosis,”Journal of Child Neurology, vol.20,no.10,pp. 822–
825, 2005.
[113] A. Mart´ ınez-Y´ elamos, A. Saiz, J. Bas, J. J. Hernandez, F.
Graus, and T. Arbizu, “Tau protein in cerebrospinal ﬂuid:
a possible marker of poor outcome in patients with early
relapsing-remitting multiple sclerosis,” Neuroscience Letters,
vol. 363, no. 1, pp. 14–17, 2004.
[114] S. D. S¨ ussmuth, H. Reiber, and H. Tumani, “Tau protein
in cerebrospinal ﬂuid (CSF): a blood-CSF barrier related
evaluation in patients with various neurological diseases,”
Neuroscience Letters, vol. 300, no. 2, pp. 95–98, 2001.
[115] A. Gajofatto, S. Monaco, M. Fiorini et al., “Assessment
of outcome predictors in ﬁrst-episode acute myelitis a
retrospective study of53cases,”Archives ofNeurology,vol.67,
no. 6, pp. 724–730, 2010.16 Multiple Sclerosis International
[116] A. Schneider, G. W. Ara´ ujo, K. Trajkovic et al., “Hyperphos-
phorylation and aggregation of tau in experimental autoim-
mune encephalomyelitis,” Journal of Biological Chemistry,
vol. 279, no. 53, pp. 55833–55839, 2004.
[117] A.Scheurich, P. P.Urban, N.Koch-Khoury, andA.Fellgiebel,
“CSFphospho-tauisindependent ofage,cognitivestatusand
gender of neurological patients,” Journal of Neurology,v o l .
257, no. 4, pp. 609–614, 2010.
[118] P. R. Turner, K. O’Connor, W. P. Tate, and W. C. Abraham,
“Roles of amyloid precursor protein and its fragments in
regulating neural activity, plasticity and memory,” Progress in
Neurobiology, vol. 70, no. 1, pp. 1–32, 2003.
[119] E. H. Koo, S. S. Sisodia, D. R. Archer et al., “Precursor
of amyloid protein in Alzheimer disease undergoes fast
anterograde axonal transport,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 87,
no. 4, pp. 1561–1565, 1990.
[120] W. Br¨ uck and C. Stadelmann, “Inﬂammation and degenera-
tion in multiple sclerosis,” Neurological Sciences, vol. 24, no.
5, pp. S265–S267, 2003.
[121] J. Gehrmann, R. B. Banati, M. L. Cuzner, G. W. Kreutzberg,
and J.Newcombe, “Amyloid precursor protein (APP) expres-
sioninmultiplesclerosislesions,”Glia,vol.15,no.2,pp.141–
151, 1995.
[122] N. Mattsson, M. Axelsson, S. Haghighi et al., “Reduced
cerebrospinal ﬂuid BACE1 activity in multiple sclerosis,”
Multiple Sclerosis, vol. 15, no. 4, pp. 448–454, 2009.
[123] U. Andreasson, E. Portelius, M. E. Andersson, K. Blennow,
and H. Zetterberg, “Aspects of beta-amyloid as a biomarker
forAlzheimer’s disease,”Biomarkers in Medicine,vol.1,no.1,
pp. 59–78, 2007.
[124] J. Kim, V. M. Miller, Y. Levites et al., “BRI2 (ITM2b) inhibits
Aβ deposition in vivo,” Journal of Neuroscience, vol. 28, no.
23, pp. 6030–6036, 2008.
[125] V. K. Harris, A. Diamanduros, P. Good, E. Zakin, V.
Chalivendra, and S. A. Sadiq, “Bri2-23 is a potential cere-
brospinalﬂuidbiomarkerinmultiplesclerosis,”Neurobiology
of Disease, vol. 40, no. 1, pp. 331–339, 2010.
[126] F. Mori, S. Rossi, G. Sancesario et al., “Cognitive and cortical
plasticity deﬁcits correlate with altered amyloid-β CSF levels
in multiple sclerosis,” Neuropsychopharmacology, vol. 36, no.
3, pp. 559–568, 2011.
[127] T. Tokuda, T. Oide, A. Tamaoka, K. Ishii, S. Matsuno, and S.
Ikeda, “Prednisolone (30–60 mg/day) for diseases other than
AD decreases amyloid β-peptides in CSF,” Neurology, vol. 58,
no. 9, pp. 1415–1418, 2002.
[128] C. Bjartmar, J. Battistuta, N. Terada, E. Dupree, and B.
D. Trapp, “N-acetylaspartate is an axon-speciﬁc marker of
mature white matter in vivo: a biochemical and immunohis-
tochemicalstudy ontheratopticnerve,”Annals ofNeurology,
vol. 51, no. 1, pp. 51–58, 2002.
[129] J. R. Moﬀe t t ,B .R o s s ,P .A r u n ,C .N .M a d h a v a r a o ,a n dA .
M. A. Namboodiri, “N-Acetylaspartate in the CNS: from
neurodiagnostics to neurobiology,” Progress in Neurobiology,
vol. 81, no. 2, pp. 89–131, 2007.
[130] D. J. Rigotti, M. Inglese, and O. Gonen, “Whole-brain N-
acetylaspartate as a surrogate marker of neuronal damage in
diﬀuse neurologic disorders,” American Journal of Neuroradi-
ology, vol. 28, no. 10, pp. 1843–1849, 2007.
[131] O. Khan, Y. Shen, C. Caon et al., “Axonal metabolic recovery
and potential neuroprotective eﬀect of glatiramer acetate
in relapsing-remitting multilple sclerosis,” Multiple Sclerosis,
vol. 11, no. 6, pp. 646–651, 2005.
[132] M. Tiberio, D. T. Chard, D. R. Altmann et al., “Metabolite
changes in early relapsing-remitting multiple sclerosis: a two
year follow-up study,” Journal of Neurology, vol. 253, no. 2,
pp. 224–230, 2006.
[133] D. J. Rigotti, O. Gonen, R. I. Grossman et al., “Global N-
acetylaspartate declines even in benign multiple sclerosis,”
American Journal of Neuroradiology, vol. 32, no. 1, pp. 204–
209, 2011.
[134] M. Van Au Duong, B. Audoin, Y. Le Fur et al., “Relationships
between gray matter metabolic abnormalities and white
matterinﬂammationinpatients atthevery early stageofMS:
aM R S Is t u d y , ”Journal of Neurology, vol. 254, no. 7, pp. 914–
923, 2007.
[135] K. Viala,J.L.Stievenart, E. A. Cabanis,O. Lyon-Caen,and A.
Tourbah, “Study with localized proton magnetic resonance
spectroscopy of 31 multiple sclerosis lesions: correlations
withclinicalandMRIfeatures,”Revue Neurologique,vol.157,
no. 1, pp. 35–44, 2001.
[136] N. De Stefano, P. M. Matthews, L. Fu et al., “Axonal damage
correlates with disability in patients with relapsing-remitting
multiple sclerosis. Results of a longitudinal magnetic reso-
nance spectroscopy study,” Brain, vol. 121, no. 8, pp. 1469–
1477, 1998.
[137] N. De Stefano,S.Narayanan,G. S.Francis et al.,“Evidence of
axonaldamage in the early stages of multiple sclerosis and its
relevance to disability,” Archives of Neurology, vol. 58, no. 1,
pp. 65–70, 2001.
[138] N. De Stefano, G. Iannucci, M. P. Sormani et al., “MR
correlates of cerebral atrophy in patients with multiple
sclerosis,” Journal of Neurology, vol. 249, no. 8, pp. 1072–
1077, 2002.
[139] S. Narayanan, N. De Stefano, G. S. Francis et al., “Axonal
metabolic recovery in multiple sclerosis patients treated with
interferon β-1b,” Journal of Neurology, vol. 248, no. 11, pp.
979–986, 2001.
[140] M. Colucci, L. Roccatagliata, E. Capello et al., “The 14-3-3
protein in multiple sclerosis: a marker of disease severity,”
Multiple Sclerosis, vol. 10, no. 5, pp. 477–481, 2004.
[141] B. Jasperse, C. Jakobs, M. J. Eikelenboom et al., “N-
acetylaspartic acid in cerebrospinal ﬂuid of multiple sclerosis
patientsdeterminedbygas-chromatography-massspectrom-
etry,” Journal of Neurology, vol.254,no.5, pp. 631–637,2007.
[142] R. T. Cunningham, J. I. Morrow, C. F. Johnston, and K. D.
Buchanan, “Serum neurone-speciﬁc enolase concentrations
in patients with neurological disorders,” Clinica Chimica
Acta, vol. 230, no. 2, pp. 117–124, 1994.
[143] M. Koch, J. Mostert, D. Heersema, A. Teelken, and J. De
Keyser, “Plasma S100β and NSE levels and progression in
multiple sclerosis,” Journal of the Neurological Sciences,v o l .
252, no. 2, pp. 154–158, 2007.
[144] P. J. H. Jongen, K. J. B. Lamers, W. H. Doesburg, W. A.
J. G. Lemmens, and O. R. Hommes, “Cerebrospinal ﬂuid
analysis diﬀerentiates between relapsing-remitting and sec-
ondary progressive multiple sclerosis,” Journal of Neurology
Neurosurgery and Psychiatry, vol. 63, no. 4, pp. 446–451,
1997.
[145] V. I. Zannis, “Genetic polymorphism in human apolipopro-
tein E,” Methods in Enzymology, vol. 128, pp. 823–851, 1986.
[146] H. L. Zhang, J. Wu, and J. Zhu, “The immune-modulatory
role of apolipoprotein e with emphasis on multiple sclerosis
and experimental autoimmune encephalomyelitis,” Clini-
cal and Developmental Immunology, vol. 2010, Article ID
186813, 2010.Multiple Sclerosis International 17
[147] M. Mulder, A. Blokland, D. J. Van Den Berg et al., “Apol-
ipoprotein E protects against neuropathology induced by a
high-fat diet and maintains the integrity of the blood-brain
barrier during aging,” Laboratory Investigation,v o l .8 1 ,n o .7 ,
pp. 953–960, 2001.
[148] B. B. Gelman, N. Rifai, R. H. Christenson, and L. M.
Silverman, “Cerebrospinal ﬂuid and plasma apolipoproteins
in patients with multiple sclerosis,” Annals of Clinical and
Laboratory Science, vol. 18, no. 1, pp. 46–52, 1988.
[149] J. Carlsson, V. W. Armstrong, H. Reiber, K. Felgenhauer,
and D. Seidel, “Clinical relevance of the quantiﬁcation of
apolipoprotein E in cerebrospinal ﬂuid,” Clinica Chimica
Acta, vol. 196, no. 2-3, pp. 167–176, 1991.
[150] P. Hogh, A. Oturai, K. Schreiber et al., “Apoliprotein E
and multiple sclerosis: impact of the epsilon-4 allele on
susceptibility, clinical type and progression rate,” Multiple
Sclerosis, vol. 6, no. 4, pp. 226–230, 2000.
[151] N. De Stefano, M. L. Bartolozzi,B. Nacmias et al., “Inﬂuence
of apolipoprotein E ε4 genotype on brain tissue integrity in
relapsing-remitting multiple sclerosis,”Archives of Neurology,
vol. 61, no. 4, pp. 536–540, 2004.
[152] E. Portaccio, V. Zipoli, B. Goretti et al., “ApolipoproteinE
epsilon 4 allele is not associated with disease course and
severity in multiple sclerosis,”Acta Neurologica Scandinavica,
vol. 120, no. 6, pp. 439–441, 2009.
[153] F.Fazekas,S.Strasser-Fuchs,H.Kolleggeretal.,“Apolipopro-
tein E ε4 is associated with rapid progression of multiple
sclerosis,”Neurology, vol. 57, no. 5, pp. 853–857, 2001.
[154] M. Pinholt, J. L. Frederiksen, P. S. Andersen, and M.
Christiansen, “Apo E in multiple sclerosis and optic neuritis:
the Apo E-ε4 allele is associated with progression of multiple
sclerosis,”Multiple Sclerosis, vol.11,no.5,pp. 511–515,2005.
[155] C. Enzinger, S. Ropele, S. Strasser-Fuchs et al., “Lower levels
of N-acetylaspartate in multiple sclerosis patients with the
apolipoprotein E ε4 allele,” Archives of Neurology, vol. 60, no.
1, pp. 65–70, 2003.
[156] A. Sena, R. Couderc, V. Ferret-Sena et al., “Apolipoprotein
e polymorphisminteracts with cigarette smokingin progres-
sionofmultiplesclerosis,”European Journal of Neurology,v ol.
16, no. 7, pp. 832–837, 2009.
[157] J. Shi, C. B. Zhao, T. L. Vollmer, T. M. Tyry, and S. M.
Kuniyoshi, “APOE ε4 allele is associated with cognitive
impairment in patients with multiple sclerosis,” Neurology,
vol. 70, no. 3, pp. 185–190, 2008.
[158] E. Portaccio, B. Goretti, V. Zipoli et al., “APOE-ε4i s
not associated with cognitive impairment in relapsing—
remitting multiple sclerosis,” Multiple Sclerosis, vol. 15, no.
12, pp. 1489–1494, 2009.
[159] O. Gaillard, A. Gervais, D. Meillet et al., “Apolipoprotein E
and multiple sclerosis: a biochemical and genetic investiga-
tion,” Journal of the Neurological Sciences, vol. 158, no. 2, pp.
180–186, 1998.
[160] N. Rifai, R. H. Christenson, B. B. Gelman, and L. M. Silver-
man,“ChangesincerebrospinalﬂuidIgG andapolipoprotein
E indices in patients with multiple sclerosis during demyeli-
nation and remyelination,” Clinical Chemistry,v o l .3 3 ,n o .7 ,
pp. 1155–1157, 1987.
[161] D. Chiasserini, M. Di Filippo, A. Candeliere et al., “CSF
proteome analysis in multiple sclerosis patients by two-
dimensionalelectrophoresis,” European Journal of Neurology,
vol. 15, no. 9, pp. 998–1001, 2008.
[162] G. Giovannoni, “Multiple sclerosis cerebrospinal ﬂuid bio-
markers,” Disease Markers, vol. 22, no. 4, pp. 187–196, 2006.
[163] V. Hoﬀmann, W. Kuhn, S. Schimrigk et al., “Repeat intrathe-
cal triamcinolone acetonide application is beneﬁcial in pro-
gressive MS patients,” European Journal of Neurology, vol. 13,
no. 1, pp. 72–76, 2006.
[164] B. G. M. Van Engelen, K. J. B. Lamers, F. J. M. Gabreels,
R .A .W e v e r s ,W .J .A .V a nG e e l ,a n dG .F .B o r m ,“ A g e -
related changes of neuron-speciﬁc enolase, S-100 protein,
and myelin basic protein concentrations in cerebrospinal
ﬂuid,” Clinical Chemistry, vol. 38, no. 6, pp. 813–816, 1992.
[165] J. Finsterer, M. Exner, and H. Rumpold, “Cerebrospinal ﬂuid
neuron-speciﬁc enolase in non-selected patients,” Scandina-
vian Journal of Clinical and Laboratory Investigation, vol. 64,
no. 6, pp. 553–558, 2004.
[166] A. B. Oestreicher, P. N. E. De Graan, W. H. Gispen, J.
Verhaagen, and L. H. Schrama, “B-50, the growth associated
protein-43:modulationofcellmorphologyandcommunica-
tion in the nervous system,” Progress in Neurobiology, vol. 53,
no. 6, pp. 627–686, 1997.
[167] C. E. Teunissen, C. D. Dijkstra, B. Jasperse et al., “Growth-
associated protein 43 in lesions and cerebrospinal ﬂuid in
multiple sclerosis,” Neuropathology and Applied Neurobiol-
ogy, vol. 32, no. 3, pp. 318–331, 2006.
[168] V. Leoni, “Oxysterols as markers of neurological disease—
ar e v i e w , ”Scandinavian Journal of Clinical and Laboratory
Investigation, vol. 69, no. 1, pp. 22–25, 2009.
[169] V. D. Karrenbauer, V. Leoni, EE. T. Lim et al., “Plasma
cerebrosterol and magnetic resonance imaging measures in
multiple sclerosis,” Clinical Neurology and Neurosurgery,v o l .
108, no. 5, pp. 456–460, 2006.
[170] L. Bretillon, ˚ A. Sid´ en, L. O. Wahlund et al., “Plasma levels
of 24S-hydroxycholesterol in patients with neurological
diseases,” Neuroscience Letters, vol. 293, no. 2, pp. 87–90,
2000.
[171] V. Leoni, T. Masterman, U. Diczfalusy, G. De Luca, J. Hillert,
and I. Bj¨ orkhem, “Changes in human plasma levels of
the brain speciﬁc oxysterol 24S-hydroxycholesterol during
progression of multiple sclerosis,” Neuroscience Letters,v o l .
331, no. 3, pp. 163–166, 2002.
[172] C.E.Teunissen,C.D.Dijkstra,C.H.Polman,E.L.J.Hooger-
vorst,K.VonBergmann,andD.L¨ utjohann,“Decreased levels
of the brain speciﬁc 24S-hydroxycholesterol and cholesterol
precursors in serum of multiple sclerosis patients,” Neuro-
science Letters, vol. 347, no. 3, pp. 159–162, 2003.
[173] V. Leoni, T. Masterman, F. S. Mousavi et al., “Diagnostic use
of cerebral and extracerebral oxysterols,” Clinical Chemistry
and Laboratory Medicine, vol. 42, no. 2, pp. 186–191, 2004.
[174] J. De Seze, K. Peoc’h, D. Ferriby, T. Stojkovic,J. L. Laplanche,
and P. Vermersch, “14-3-3 Protein in the cerebrospinal
ﬂuid of patients with acute transverse myelitis and multiple
sclerosis,” Journal of Neurology, vol. 249, no. 5, pp. 626–627,
2002.
[175] A. Mart´ ınez-Y´ elamos, A. Saiz, R. Sanchez-Valle et al., “14-3-
3 Protein in the CSF as prognostic marker in early multiple
sclerosis,” Neurology, vol. 57, no. 4, pp. 722–724, 2001.
[176] A. Mart´ ınez-Y´ elamos, A. Rovira, R. S´ anchez-Valle et al.,
“CSF 14-3-3 protein assay and MRI as prognostic markers
in patients with a clinically isolated syndrome suggestive of
MS,” Journal of Neurology, vol. 251, no. 10, pp. 1278–1279,
2004.
[177] L. Bretillon, D. L¨ utjohann, L. St˚ ahle et al., “Plasma levels of
24S-hydroxycholesterol reﬂect the balance between cerebral
production and hepatic metabolism and are inversely related
to body surface,” Journal of Lipid Research,v o l .4 1 ,n o .5 ,p p .
840–845, 2000.18 Multiple Sclerosis International
[178] I. Bj¨ orkhem, S. Meaney, and A. M. Fogelman, “Brain choles-
terol: long secret life behind a barrier,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol.24, no. 5, pp. 806–815,
2004.
[179] V. Leoni, T. Masterman, P. Patel, S. Meaney, U. Diczfalusy,
and I. Bj¨ orkhem, “Side chain oxidized oxysterols in cere-
brospinal ﬂuid and the integrity of blood-brain and blood-
cerebrospinal ﬂuid barriers,” Journal of Lipid Research,v o l .
44, no. 4, pp. 793–799, 2003.
[180] P. F. Boston, P. Jackson, and R. J. Thompson, “Human 14-3-
3 protein: radioimmunoassay, tissue distribution, and cere-
brospinalﬂuidlevelsinpatientswith neurologicaldisorders,”
Journal of Neurochemistry, vol. 38, no. 5, pp. 1475–1482,
1982.
[181] J.I.Satoh,K.Kurohara,M.Yukitake,andY.Kuroda,“The14-
3-3 protein detectable in the cerebrospinal ﬂuid of patients
with prion-unrelated neurological diseases is expressed con-
stitutively in neurons and glial cells in culture,” European
Neurology, vol. 41, no. 4, pp. 216–225, 1999.
[182] J.-I. Satoh, T. Yamamura, and K. Arima, “The 14-3-3 protein
ε isoform expressed in reactive astrocytes in demyelinating
lesions of multiple sclerosis binds to vimentin and glial
ﬁbrillary acidic protein in cultured human astrocytes,”
American Journal of Pathology, vol. 165, no. 2, pp. 577–592,
2004.
[183] H. Slaets, D. Dumont, J. Vanderlocht et al., “Leukemia
inhibitory factor induces an antiapoptotic response in
oligodendrocytes through Akt-phosphorylation and up-
regulationof14-3-3,”Proteomics,vol.8,no.6,pp.1237–1247,
2008.
[184] J. M. Woodcock, Y. Ma, C. Coolen et al., “Sphingosine and
FTY720directly bindpro-survival14-3-3proteins toregulate
their function,” Cellular Signalling, vol. 22, no. 9, pp. 1291–
1299, 2010.
[185] F.Deisenhammer,R.Egg,G.Giovannonietal.,“EFNS guide-
lines on disease-speciﬁc CSF investigations,” European Jour-
nal of Neurology, vol. 16, no. 6, pp. 760–770, 2009.
[186] A. Saiz, F. Graus, J. Dalmau, A. Pifarr´ e, C. Mar´ ın, and
E. Tolosa, “Detection of 14-3-3 brain protein in the cere-
brospinal ﬂuid of patients with paraneoplastic neurological
disorders,” Annals of Neurology, vol. 46, no. 5, pp. 774–777,
1999.
[187] J. I. Satoh, M. Yukitake, K. Kurohara, H. Takashima, and Y.
Kuroda,“Detection ofthe14-3-3protein inthecerebrospinal
ﬂuid of Japanese multiple sclerosis patients presenting with
severe myelitis,” Journal of the Neurological Sciences, vol. 212,
no. 1-2, pp. 11–20, 2003.
[188] D. N. Irani and D. A. Kerr, “14-3-3 Protein in the cere-
brospinal ﬂuid of patients with acute transverse myelitis,”
Lancet, vol. 355, no. 9207, p. 901, 2000.
[189] B. N. Hammack, K. Y. C. Fung, S. W. Hunsucker et al.,
“Proteomicanalysisofmultiplesclerosiscerebrospinal ﬂuid,”
Multiple Sclerosis, vol. 10, no. 3, pp. 245–260, 2004.
[190] D. Dumont, J. P. Noben, J. Raus, P. Stinissen, and J. Robben,
“Proteomic analysis of cerebrospinal ﬂuid from multiple
sclerosis patients,” Proteomics, vol. 4, no. 7, pp. 2117–2124,
2004.
[191] A. J. Elderﬁeld, J. Newcombe, C. Bolton, and R. J. Flower,
“Lipocortins (annexins) 1, 2, 4 and 5 are increased in the
central nervous system in multiple sclerosis,” Journal of
Neuroimmunology, vol. 39, no. 1-2, pp. 91–100, 1992.
[192] M.J.Craner, A. C. Lo,J.A. Blacket al.,“Annexin II/PIIis up-
regulated in Purkinje cells inEAE andMS,”NeuroReport,v o l .
14, no. 4, pp. 555–558, 2003.
[193] J. P. Noben, D. Dumont, N. Kwasnikowska et al., “Lumbar
cerebrospinal ﬂuid proteome in multiple sclerosis:character-
ization by ultraﬁltration, liquid chromatography, and mass
spectrometry,” Journal of Proteome Research,v o l .5 ,n o .7 ,p p .
1647–1657, 2006.
[194] S. Elkabes and H. Li, “Proteomic strategies in multiple
sclerosis and its animal models,” Proteomics,v o l .1 ,n o .1 1 ,
pp. 1393–1405, 2007.
[195] N. Mattsson, U. R¨ uetschi, V. N. Podust et al., “Cerebrospinal
ﬂuid concentrations of peptides derived from chromogranin
B and secretogranin II are decreased in multiple sclerosis,”
Journal of Neurochemistry, vol. 103, no. 5, pp. 1932–1939,
2007.
[196] E. K. Mathey, T. Derfuss, M. K. Storch et al., “Neurofascin
as a novel target for autoantibody-mediated axonal injury,”
Journal of Experimental Medicine, vol. 204, no. 10, pp. 2363–
2372, 2007.
[197] R. A. Linker,P.Brechlin, S.Jesseet al.,“Proteome proﬁlingin
murine models of multiple sclerosis: identiﬁcation of stage
speciﬁc markers and culprits for tissue damage,” PLoS ONE,
vol. 4, no. 10, article e7624, 2009.
[198] H. Tumani, C. Teunissen, S. S¨ ussmuth, M. Otto, A.
C. Ludolph, and J. Brettschneider, “Cerebrospinal ﬂuid
biomarkers of neurodegeneration in chronic neurological
diseases,” Expert Review of Molecular Diagnostics,v o l .8 ,n o .
4, pp. 479–494, 2008.
[199] H. Tumani,H.-P. Hartung, B. Hemmer et al.,“Cerebrospinal
ﬂuid biomarkers in multiple sclerosis,” Neurobiology of
Disease, vol. 35, no. 2, pp. 117–127, 2009.
[200] A. Petzold, A. Altintas, L. Andreoni et al., “Neuroﬁlament
ELISA validation,” Journal of Immunological Methods,v o l .
352, no. 1-2, pp. 23–31, 2010.
[201] C. E. Teunissen, A. Petzold, J. L. Bennett et al., “A consensus
protocol forthe standardizationofcerebrospinal ﬂuidcollec-
tion and biobanking,” Neurology, vol. 73, no. 22, pp. 1914–
1922, 2009.